**Back
          to Table of Contents**





**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**







**FORM
      10-Q**





x QUARTERLY
      REPORT PURSUANT TO SECTION 13 OR 15(d)


OF
      THE
      SECURITIES EXCHANGE ACT OF 1934





**For
      the quarterly period ended April 30, 2006**





or




o TRANSITION
      REPORT PURSUANT TO SECTION 13 OR 15(d)


OF
      THE
      SECURITIES EXCHANGE ACT OF 1934


Commission
      File Number 0-26670





**NORTH
      AMERICAN SCIENTIFIC, INC.**


(Exact
      name of registrant as specified in its charter)




Delaware
            51-0366422(State
                or other jurisdiction of
            (I.R.S.
                Employerincorporation
                or organization)
            Identification
                No.)




20200
      Sunburst Street, Chatsworth, CA 91311


(Address
      of principal executive offices)





(818)
      734-8600


(Registrant's
      telephone number, including area code)







Indicate
      by check mark whether the registrant (1) has filed all reports required to
      be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
      during the preceding 12 months (or for such shorter period that the
      registrant was required to file such reports), and (2) has been subject to
      such filing requirements for the past 90 days. x Yes o No




Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, or a non-accelerated filer. See definition of “accelerated
      filer” and “large accelerated filer” in Rule 12b-2 of the Securities
      Exchange Act of 1934. Large Accelerated Filer o Accelerated Filer x Non-Accelerated Filer o





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act. o Yes x No





The
      number of shares of Registrant's Common Stock, $.01 par value, outstanding
      as of
      June 1, 2006 was 16,988,860 shares.







**Back
        to Table of Contents**


**NORTH
      AMERICAN SCIENTIFIC, INC.**




**Index**




**Page****Part
                I - Financial Information****Item
                1.**
            **Financial
                Statements**Consolidated
                Balance Sheets as of April 30, 2006 and October
                31, 2005
            3Consolidated
                Statements of Operations for the three and six
                months ended April 30, 2006 and 2005
            4Consolidated
                Statements of Cash Flows for the six months ended
                April 30, 2006 and 2005
            5Condensed
                Notes to the Consolidated Financial
                Statements
            6**Item
                2.**
            **Management’s
                Discussion and Analysis of Financial Condition
                and Results of Operations**
            20**Item
                3.**
            **Quantitative
                and Qualitative Disclosures about Market Risk**
            28**Item
                4.**
            **Controls
                and Procedures**
            29**Part
                II - Other Information****Item
                1.**
            **Legal
                Proceedings**
            29**Item
                1A.**
            **Risk
                Factors**
            30**Item
                2.**
            **Unregistered
                Sales of Equity Securities and Use of
                Proceeds**
            48**Item
                6.**
            **Exhibits**
            48**Signatures**
            49






-2-
 **Back
          to Table of Contents**




**PART
      I - FINANCIAL INFORMATION**





**Item
      1. Financial Statements**





**NORTH
      AMERICAN SCIENTIFIC, INC.**




**Consolidated
      Balance Sheets**




**April
                30,**
            
            **October
                31,****2006**
            
            **2005**(Unaudited)**Assets**Current
                assetsCash
                and cash equivalents
            
            $
            1,753,000
            
            $
            2,630,000Marketable
                securities, held to maturity
            
            
            —
            
            
            993,000Accounts
                receivable, net of reserves
            
            
            6,784,000
            
            
            5,521,000Inventories,
                net of reserves
            
            
            3,909,000
            
            
            3,731,000Prepaid
                expenses and other current assets
            
            
            1,218,000
            
            
            794,000Total
                current assets
            
            
            13,664,000
            
            
            13,669,000Equipment
                and leasehold improvements, net of $5,993,000 and $5,522,000
            
            
            2,520,000
            
            
            2,836,000accumulated
                depreciation at April 30, 2006 and October 31, 2005, respectivelyGoodwill
            
            
            2,564,000
            
            
            2,564,000Intangible
                assets, net of $3,818,000 and $3,505,000 accumulated amortization
                at
            
            
            2,845,000
            
            
            3,158,000April
                30, 2006 and October 31, 2005, respectivelyOther
                assets
            
            
            586,000
            
            
            106,000Total
                assets
            
            $
            22,179,000
            
            $
            22,333,000**Liabilities
                and Stockholders’ Equity**Current
                liabilitiesLine
                of credit
            
            $
            3,314,000
            
            $
            —Accounts
                payable
            
            
            2,550,000
            
            
            2,164,000Accrued
                expenses
            
            
            3,242,000
            
            
            4,706,000Deferred
                revenue
            
            
            4,567,000
            
            
            4,662,000Total
                current liabilities
            
            
            13,673,000
            
            
            11,532,000Long
                Term Debt
            
            
            3,000,000
            
            
            —Total
                liabilities
            
            
            16,673,000
            
            
            11,532,000Commitments
                and contingenciesStockholders’
                EquityPreferred
                stock, $0.01 par value, 2,000,000 shares authorized; no
                sharesissued
            
            
            —
            
            
            —Common
                stock, $0.01 par value, 40,000,000 shares authorized, 17,096,886and
                17,056,669 shares issued; 16,988,860 and 16,948,643 shares outstanding
                as
                of April 30, 2006 and October 31, 2005, respectively
            
            
            174,000
            
            
            173,000Additional
                paid-in capital
            
            
            122,221,000
            
            
            121,147,000Treasury
                stock, at cost - 108,026 common shares
            
            
            (129,000
            )
            
            (129,000Accumulated
                deficit
            
            
            (116,760,000
            )
            
            (110,390,000Total
                stockholders’ equity
            
            
            5,506,000
            
            
            10,801,000Total
                liabilities and stockholders’ equity
            
            $
            22,179,000
            
            $
            22,333,000





See
      condensed notes to the consolidated financial statements.




-3-
 **Back
          to Table of Contents**


**NORTH
      AMERICAN SCIENTIFIC, INC.**




**Consolidated
      Statements of Operations**


**(Unaudited)**




**Three
                months ended April 30,**
            
            **Six
                months ended April 30,****2006**
            
            **2005**
            
            **2006**
            
            **2005**RevenueProduct
            
            $
            5,835,000
            
            $
            5,843,000
            
            $
            11,004,000
            
            $
            11,216,000Service
            
            
            2,222,000
            
            
            3,298,000
            
            
            4,580,000
            
            
            6,089,000Total
                revenue
            
            
            8,057,000
            
            
            9,141,000
            
            
            15,584,000
            
            
            17,305,000Cost
                of revenueProduct
            
            
            4,190,000
            
            
            4,603,000
            
            
            8,045,000
            
            
            8,828,000Service
            
            
            941,000
            
            
            880,000
            
            
            1,762,000
            
            
            1,890,000Total
                cost of revenue
            
            
            5,131,000
            
            
            5,483,000
            
            
            9,807,000
            
            
            10,718,000Gross
                profit
            
            
            2,926,000
            
            
            3,658,000
            
            
            5,777,000
            
            
            6,587,000Operating
                expensesSelling
                expenses
            
            
            2,331,000
            
            
            2,164,000
            
            
            4,185,000
            
            
            4,303,000General
                and administrative expenses
            
            
            2,617,000
            
            
            3,278,000
            
            
            4,811,000
            
            
            5,580,000Research
                and development
            
            
            1,416,000
            
            
            1,624,000
            
            
            2,740,000
            
            
            3,256,000Amortization
                of intangible assets
            
            
            157,000
            
            
            575,000
            
            
            314,000
            
            
            1,150,000Total
                operating expenses
            
            
            6,521,000
            
            
            7,641,000
            
            
            12,050,000
            
            
            14,289,000Loss
                from operations
            
            
            (3,595,000
            )
            
            (3,983,000
            )
            
            (6,273,000
            )
            
            (7,702,000
            )Interest
                and other income(expense)
            
            
            (100,000
            )
            
            55,000
            
            
            (97,000
            )
            
            124,000Loss
                before provision for income taxes
            
            
            (3,695,000
            )
            
            (3,928,000
            )
            
            (6,370,000
            )
            
            (7,578,000
            )Loss
                from continuing operations
            
            
            (3,695,000
            )
            
            (3,928,000
            )
            
            (6,370,000
            )
            
            (7,578,000
            )Net
                loss
            
            $
            (3,695,000
            )
            $
            (3,928,000
            )
            $
            (6,370,000
            )
            $
            (7,578,000
            )Basic
                and diluted loss per share:
            
            
            (0.22
            )
            
            (0.24
            )
            
            (0.38
            )
            
            (0.47
            )Weighted
                average number of shares outstanding
            
            
            16,988,863
            
            
            16,231,436
            
            
            16,975,087
            
            
            16,287,595




See
      condensed notes to the consolidated financial statements.




-4-
 **Back
          to Table of Contents**


**NORTH
      AMERICAN SCIENTIFIC, INC.**




**Consolidated
      Statements of Cash Flows**


**(Unaudited)**




**Six
                Months Ended April 30,****2006**
            
            **2005**Cash
                flows from operating activities:Net
                loss
            
            $
            (6,370,000
            )
            $
            (7,578,000
            )Adjustments
                to reconcile net loss to net cash used in operating
                activities:Depreciation
                and amortization
            
            
            784,000
            
            
            1,713,000Amortization
                of warrants
            
            
            47,000
            
            
            —Share-based
                compensation expense
            
            
            479,000
            
            
            —Provision
                for doubtful accounts
            
            
            450,000
            
            
            254,000Changes
                in assets and liabilities, net of discontinued operation:Accounts
                receivable
            
            
            (1,714,000
            )
            
            (350,000
            )Inventories
            
            
            (178,000
            )
            
            785,000Prepaid
                and other current assets
            
            
            (420,000
            )
            
            (427,000
            )Accounts
                payable
            
            
            384,000
            
            
            (729,000
            )Accrued
                expenses
            
            
            (1,384,000
            )
            
            (766,000
            )Deferred
                revenue
            
            
            (96,000
            )
            
            (998,000
            )Net
                cash used in continuing operations
            
            
            (8,018,000
            )
            
            (8,096,000
            )Net
                cash used in discontinued operation
            
            
            (81,000
            )
            
            (497,000
            )Net
                cash used in operating activities
            
            
            (8,099,000
            )
            
            (8,593,000
            )Cash
                flows from investing activities:Proceeds
                from maturity of marketable securities
            
            
            993,000
            
            
            6,512,000Capital
                expenditures
            
            
            (155,000
            )
            
            (200,000
            )Net
                cash provided by investing activities
            
            
            838,000
            
            
            6,312,000Cash
                flow from financing activities:Proceeds
                from line of credit
            
            
            3,314,000
            
            
            —Proceeds
                from long-term debt
            
            
            3,000,000
            
            
            —Proceeds
                from exercise of stock options and stock purchase plan
            
            
            70,000
            
            
            215,000Net
                cash provided by finance activities
            
            
            6,384,000
            
            
            215,000Net
                decrease in cash and cash equivalents
            
            
            (877,000
            )
            
            (2,066,000
            )Cash
                and cash equivalents at beginning of period
            
            
            2,630,000
            
            
            2,334,000Cash
                and cash equivalents at end of period
            
            $
            1,753,000
            
            $
            268,000





Supplemental
      disclosure:


In
      the
      six months ended April 30, 2006, the Company has issued warrants with an
      estimated fair value totaling $526,000 to a bank and a debt provider as
      consideration for entering into Loan and Security Agreements. See Note 6 to
      the
      Financial Statements.




In
      the six months ended April 30, 2006, there were no
      cash flows from investing activities or financing activities from discontinued
      operations.





See
      condensed notes to the consolidated financial statements.




-5-
 **Back
          to Table of Contents**


**NORTH
      AMERICAN SCIENTIFIC, INC.**





**Condensed
      Notes to Consolidated Financial
      Statements**


**(Unaudited)**








**NOTE
      1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**





*Subsequent
      Events*





On
      June
      7, 2006, North American Scientific, Inc.(the “Company”) closed an approximately
      $24 million private placement of shares of its common stock and the concurrent
      issuance of warrants for the purchase of additional shares of its common stock.
      Net proceeds from the financing will be used for new product development,
      including the Company’s breast brachytherapy product, and for working capital.





At
      the
      closing, the investors received 12,291,934 shares of the Company’s common stock
      at a purchase price of $1.95 per share as well as warrants to purchase an
      additional 6,145,967 shares of the Company’s common stock at an exercise price
      of $2.08 per share, which are exercisable beginning 180 days after the date
      of
      closing until 7 years after the date of closing.





The
      securities sold in this private placement have not been registered under the
      Securities Act of 1933, as amended, and may not be offered or sold in the United
      States in the absence of an effective registration statement or exemption from
      registration requirements. The Company agreed to file a registration statement
      after the closing of the transaction for purposes of registering the resale
      of
      the shares of common stock issued in the private placement and the shares of
      common stock issuable upon exercise of the warrants.





*Basis
      of Presentation*





The
      accompanying consolidated financial statements of the Company are unaudited,
      other than the consolidated balance sheet at October 31, 2005, and reflect
      all
      material adjustments, consisting only of normal recurring adjustments, which
      management considers necessary for a fair statement of the Company’s financial
      position, results of operations and cash flows for the interim periods. The
      results of operations for the current interim periods are not necessarily
      indicative of the results to be expected for the entire fiscal
      year.





These
      consolidated financial statements have been prepared in accordance with the
      rules and regulations of the Securities and Exchange Commission (“SEC”). Certain
      information and footnotes normally included in financial statements prepared
      in
      accordance with generally accepted accounting principles in the United States
      of
      America have been condensed or omitted pursuant to these rules and regulations.
      These consolidated financial statements should be read in conjunction with
      the
      consolidated financial statements and the notes thereto included in the
      Company’s Form 10-K, as filed with the SEC for the year ended October 31,
      2005.





Certain
      reclassifications have been made to prior period balances in order to conform
      to
      the current period presentation.





*Management’s
      Plans*





The
      accompanying financial statements have been prepared on a going concern basis,
      which contemplates the realization of assets and liquidation of liabilities
      in
      the normal course of business. However, the Company has continued to incur
      substantial net losses and used substantial amounts of cash. As of
      April




-6-
 **Back
          to Table of Contents**


30,
      2006,
      the Company has an accumulated deficit of $116.7 million, cash and cash
      equivalents of $1.8 million, $3.3 million of short-term debt and $3.0 million
      of
      long-term debt.





Especially
      in view of our recent private placement of common stock, based on the Company’s
      current operating plans, management believes that the existing cash resources,
      cash forecasted by the Company’s plans to be generated by operations, the
      issuance of the Company’s common stock and/or debt, as well as the Company’s
      anticipated and available lines of credit, will be sufficient to meet working
      capital and capital requirements through at least the next twelve months.
 Also, management’s plans to attain profitability and generate additional
      cash flows include increasing revenues from existing and new products and
      services and a focus on cost control.  There is no assurance that
      management will be successful with these plans.  However, if events and
      circumstances occur such that the Company does not meet our current operating
      plans as expected, and the Company is unable to raise additional debt or equity
      financing, the Company may be required to further reduce expenses or take other
      steps which could have a material adverse effect on the Company’s future
      performance, including but not limited to, the premature sale of some or all
      of
      the Company’s assets or product lines on undesirable terms, merger with or
      acquisition by another company on unsatisfactory terms, or the cessation of
      operations.





*Use
      of Estimates*





In
      the
      normal course of preparing the financial statements in conformity with generally
      accepted accounting principles in the United States of America, management
      is
      required to make estimates and assumptions that affect the reported amounts
      of
      assets and liabilities and disclosure of contingent assets and liabilities
      at
      the date of the financial statements and reported amounts of revenue and
      expenses during the reporting period. Actual results could differ from those
      amounts.





*Accounting
      for Stock-based Compensation*





Effective
      November 1, 2005, the Company adopted Statement of Financial Accounting
      Standards (“SFAS”) No. 123(R), *Share-Based
      Payment* (“SFAS
      123(R)”), which requires the measurement and recognition of compensation expense
      for all share-based payment awards made to employees and directors, including
      stock options and employee stock purchases related to the Company’s Employee
      Stock Purchase Plan (the “Employee Stock Purchase Plan”) based on their fair
      values. SFAS 123(R) supersedes Accounting Principles Board Opinion No. 25, *Accounting
      for Stock Issued to Employees* (“APB
      25”), which the Company previously followed in accounting for stock-based
      awards. In March 2005, the SEC issued *Staff
      Accounting Bulletin No. 107* (“SAB
      107”) to provide guidance on SFAS 123(R). The Company has applied SAB 107 in its
      adoption of SFAS 123(R).





The
      Company adopted SFAS 123(R) using the modified prospective transition method
      as
      of and for the six months ended April 30, 2006. In accordance with the modified
      prospective transition method, the Company’s financial statements for prior
      periods have not been restated to reflect, and do not include, the impact of
      SFAS 123(R). Share-based compensation expense recognized is based on the value
      of the portion of share-based payment awards that is ultimately expected to
      vest. Share-based compensation expense recognized in the Company’s Condensed
      Consolidated Statement of Operations during the six months ended April 30,
      2006
      includes compensation expense for share-based payment awards granted prior
      to,
      but not yet vested as of, October 31, 2005 based on the grant date fair value
      estimated in accordance with the pro forma provisions of SFAS 123 and new stock
      option grants made during the six months ended April 30, 2006. A total of
      1,303,000 stock option grants were awarded to employees on March 16, 2006.





In
      conjunction with the adoption of SFAS 123(R), the Company elected to attribute
      the value of share-based compensation to expense using the straight-line method,
      which was previously used for its pro forma information required under SFAS
      123
      and SFAS 148. Share-based compensation expense related




-7-
 **Back
          to Table of Contents**


to
      stock
      options and employee stock purchases was $221,000 for the 3 months ended April
      30, 2006 and $479,000 for the six months ended April 30, 2006, and was recorded
      in the financial statements as a component of general and administrative
      expense. Note that for the three months ended April 30, 2006, a total of 651,500
      stock options were granted that contain certain performance requirements,
      therefore no share-based compensation expense has been calculated on these
      stock
      options.





During
      the six months ended April 30, 2005, there was no share-based compensation
      expense related to stock options and employee stock purchases recognized under
      the intrinsic value method in accordance with APB 25. Had compensation cost
      for the Company’s stock options been recognized based upon the estimated fair
      value on the grant date under the fair value methodology prescribed by SFAS
      No.
      123, as amended by SFAS No. 148, the Company’s net loss and loss per share would
      have been as follows:





**Three
                Months Ended**
              **April
                30, 2005**
            
            **Six
                Months Ended**
              **April
                30, 2005**Net
                loss, as reported
            
            $
            (3,928,000
            )
            $
            (7,578,000
            )Less:
                total stock-based compensation (1)
            
            
            (316,000
            )
            
            (758,000
            )Net
                loss, as adjusted
            
            $
            (4,244,000
            )
            $
            (8,336,000
            )Basic
                and diluted loss per share, as reported
            
            $
            (0.24
            )
            $
            (0.47
            )Basic
                and diluted loss per share, as adjusted
            
            $
            (0.26
            )
            $
            (0.51
            )





(1)
            As
                determined under the fair value
                method.





The
      Company uses the Black-Scholes option-pricing model for estimating the fair
      value of options granted. The Black-Scholes option-pricing model was developed
      for use in estimating the fair value of traded options that have no vesting
      restrictions and are fully transferable. In addition, option valuation models
      require the input of highly subjective assumptions, including the expected
      stock
      price volatility. The Company uses projected volatility rates, which are based
      upon historical volatility rates, trended into future years. Because the
      Company’s employee stock options have characteristics significantly different
      from those of traded options, and because changes in the subjective input
      assumptions can materially affect the fair value estimate, in management’s
      opinion, the existing models do not necessarily provide a reliable single
      measure of the fair value of the Company’s options. For purposes of pro forma
      disclosures, the estimated fair values of the options are amortized over the
      options’ vesting periods.





*Revenue
      Recognition*





The
      Company sells products and services for radiation therapy treatment of cancer,
      including intensity modulated radiation therapy (“IMRT”), image guided radiation
      therapy (“IGRT”), as well as brachytherapy. Product revenue consists of
      brachytherapy seeds and accessories, non-therapeutic sources, and certain IMRT
      hardware devices, including our MiMIC and Crane products. Software revenues
      consist of IMRT treatment planning software, including Corvus, Peregrine and
      Peacock, and our IGRT products. Service revenue consists of warranty revenue
      and
      maintenance service agreements.





*Product
      revenue*





The
      Company applies the provisions of SEC Staff Accounting Bulletin (“SAB”) No. 104,
“Revenue Recognition” for the sale of non-software products. SAB 104 which
      supersedes SAB No. 101, “Revenue Recognition in Financial Statements”, provides
      guidance on the recognition, presentation and disclosure of revenue in financial
      statements. SAB No. 104 outlines the basic criteria that must be met to
      recognize revenue and provides guidance for the disclosure of revenue
      recognition policies. In general, the Company recognizes revenue related to
      product sales when (i) persuasive evidence of an arrangement exists, (ii)
      delivery has occurred, (iii) the fee is fixed or determinable, and (iv)
      collectibility is reasonably assured.




-8-
 **Back
          to Table of Contents**


*Software
      revenue*





The
      Company’s software product revenue is generated from the sale of advanced
      medical equipment products. The software element of the Company’s products is
      deemed an essential element of the functionality of the product. Maintenance
      and
      support are provided with the initial product sale for a twelve month period.
      The maintenance and support is renewable annually or longer, at the customer’s
      discretion.





The
      Company recognizes software revenue in accordance with the provisions of
      Statement of Position 97-2 (“SOP 97-2”), “Software Revenue Recognition”, as
      amended by Statement of Position 98-9 (“SOP 98-9”), “Modification of SOP 97-2,
      Software Revenue Recognition, with respect to Certain Transactions”. Under the
      provisions of SOP 97-2, the Company recognizes software revenue upon delivery
      and acceptance, provided all significant obligations have been met, persuasive
      evidence of an arrangement exists, fees are fixed or determinable, collection
      is
      probable, and the Company is not involved in providing services that are
      essential to the functionality of the product.





The
      Company’s software sales are generally multiple element arrangements, which
      could include the product, first year annual maintenance and support, and
      training and installation. Revenues from the multiple elements arrangements
      are
      allocated to each element based on the relative fair value of the elements.
      If
      the fair value of the element exists, the determination is based on vendor
      specific objective evidence. If such evidence of fair value for each element
      of
      the arrangement does not exist, all revenue from the arrangement is deferred
      until such time that evidence of fair value of each element does exist or until
      all elements of the arrangement are delivered. If in a multiple element
      arrangement, fair value does not exist for one or more of the undelivered
      elements, the residual method of accounting is applied. Under the residual
      method, the fair value of the undelivered elements is deferred, and the
      remaining portion of the arrangement fee is recognized as revenue.





*Service
      Revenue*





Services
      revenues are derived mainly from maintenance and support contracts and are
      recognized on a straight-line basis over the term of the contract. Payments
      for
      maintenance revenues are normally received in advance and are nonrefundable.





*Recent
      Accounting Pronouncements*





In
      February 2006, the FASB issued SFAS No. 155, “Accounting for Certain Hybrid
      Financial Instruments” (“SFAS 155”), which amends SFAS No. 133, “Accounting for
      Derivatives Instruments and Hedging Activities” (“SFAS 133”) and SFAS No. 140,
“Accounting for Transfers and Servicing of Financial Assets and Extinguishment
      of Liabilities” (“SFAS 140).  SFAS 155 amends SFAS 133 to narrow the scope
      exception for interest-only and principal-only strips on debt instruments to
      include only such strips representing rights to receive a specified portion
      of
      the contractual interest or principle cash flows.  SFAS 155 also amends
      SFAS 140 to allow qualifying special-purpose entities to hold a passive
      derivative financial instrument pertaining to beneficial interests that itself
      is a derivative instruments. The
      Company is currently evaluating the impact this new Standard, but believes
      that
      it will not have a material impact on the Company’s financial position, results
      of operations or cash flows.





In
      March
      2006, the FASB issued SFAS No. 156, “ Accounting
      for Servicing of Financial Assets” (“SFAS NO. 156”), which provides an approach
      to simplify efforts to obtain hedge-like (offset) accounting. This Statement
      amends FASB Statement No. 140, “Accounting for Transfers and Servicing of
      Financial Assets and Extinguishments of Liabilities”, with respect to the
      accounting for separately recognized servicing assets and servicing liabilities.
      The Statement (1) requires an entity to recognize a servicing






-9-
 **Back
          to Table of Contents**


asset
      or
      servicing liability each time it undertakes an obligation to service a financial
      asset by entering into a servicing contract in certain situations; (2) requires
      that a separately recognized servicing asset or servicing liability be initially
      measured at fair value, if practicable; (3) permits an entity to choose either
      the amortization method or the fair value method for subsequent measurement
      for
      each class of separately recognized servicing assets or servicing liabilities;
      (4) permits at initial adoption a one-time reclassification of
      available-for-sale securities to trading securities by an entity with recognized
      servicing rights, provided the securities reclassified offset the entity’s
      exposure to changes in the fair value of the servicing assets or liabilities;
      and (5) requires separate presentation of servicing assets and servicing
      liabilities subsequently measured at fair value in the balance sheet and
      additional disclosures for all separately recognized servicing assets and
      servicing liabilities. SFAS No. 156 is effective for all separately recognized
      servicing assets and liabilities as of the beginning of an entity’s fiscal year
      that begins after September 15, 2006, with earlier adoption permitted in certain
      circumstances. The Statement also describes the manner in which it should be
      initially applied. The Company does not believe that SFAS No. 156 will have
      a
      material impact on its financial position, results of operations or cash
      flows.




**NOTE
      2** - **VARIABLE
      INTEREST ENTITY**




In
      October 2003, the Company entered into a Secured Loan Agreement with Prostate
      Centers of America (“PCA”).  Under the agreement, the Company was obligated
      to make periodic advances subject to PCA achieving certain milestones.  On
      January 20, 2006, the Company received notice from PCA that it had filed for
      protection under the bankruptcy law. As of January 31, 2006, the Company’s
      advances to PCA under the secured note totaling $950,000 have been written
      off.
      The Company has no equity interest in PCA.




TC2B,
      LLC, a distributor who has agreed to procure all of its brachytherapy seeds
      exclusively from the Company through October 2008, has a majority interest
      in
      PCA. On April 30, 2006, total trade receivables due from TC2B of $1.1 million
      had been written off to the allowance for doubtful accounts and no sales to
      TC2B
      during the six months ended April 30, 2006 had been recognized. Based on the
      terms of the lending and supply agreements with the above entities, the Company
      previously determined that PCA is a variable interest entity (“VIE”) and the
      Company is the primary beneficiary under FIN No. 46 because PCA does not
      have sufficient equity at risk for the entity to finance its activities.





FIN
      46
      requires that an enterprise consolidate a VIE if that enterprise has a variable
      interest that will absorb a majority of the entity’s expected losses if they
      occur. Accordingly, the Company adopted FIN No. 46 in October 2003 and
      consolidated PCA as a VIE, regardless of the Company not having an equity
      interest in PCA and its creditors having no recourse against the Company. In
      the
      fiscal year ended October 31, 2005, the Company determined that PCA was no
      longer a VIE, because: (i) during the fiscal year ended October 31, 2005, other
      outside parties provided additional funding to PCA, which resulted in the
      Company no longer being the holder of the variable interest that would hold
      the
      majority of the entity’s losses, (ii) PCA’s other creditors have no recourse
      against the Company, (iii) the Company has no equity interest in PCA, and (iv)
      PCA had informed the Company that it likely will cease operations in 2006.
      As a
      result, the Company did not consolidate PCA as a VIE in its financial statements
      for the fiscal year ended October 31, 2005.





No
      amounts related to PCA were included in the Company’s consolidated balance
      sheets at April 30, 2006, and October 31, 2005.





**NOTE
      3 - MARKETABLE SECURITIES**





The
      Company invests excess cash in marketable securities consisting primarily of
      commercial paper, corporate notes and bonds, U.S. Government securities and
      money market funds. Investments with




-10-
 **Back
          to Table of Contents**


remaining
      maturities of less than one year are considered to be short term and are
      classified as current assets.





Debt
      securities that the Company has the positive intent and ability to hold to
      maturity are classified as “held-to-maturity” and reported at amortized cost.
      Debt securities not classified as held-to-maturity and marketable equity
      securities are classified as “available-for-sale,” are recorded at fair value
      with unrealized gains and losses included in earnings or stockholders’ equity,
      respectively. All other equity securities are accounted for using either the
      cost method or the equity method.





The
      Company continually reviews its investments to determine whether a decline
      in
      fair value below the cost basis is other than temporary. If the decline in
      fair
      value is judged to be other than temporary, the cost basis of the security
      is
      written down to fair value and the amount of the write-down is included in
      the
      Consolidated Statements of Operations.





**NOTE
      4 - ACCOUNTS RECEIVABLE**





Accounts
      receivable are recorded at the invoiced amount and do not bear interest. The
      allowance for doubtful accounts is the Company’s best estimate of the amount of
      probable credit losses in our existing accounts receivable. The Company
      determines the allowance based on historical write-off experience and customer
      economic data. We review our allowance for doubtful accounts monthly. Past
      due
      balances over 60 days and over a specified amount are reviewed individually
      for
      collectibility. Account balances are charged off against the allowance when
      the
      Company believes that it is probable the receivable will not be recovered. On
      April
      30, 2006, total trade receivables due from TC2B of $1.1 million had been written
      off to the allowance for doubtful accounts (see
      Note 2). The Company does not have any off-balance-sheet credit exposure related
      to our customers.





Accounts
      receivable consist of the following:





**April
                30,**
            
            **October
                31,****2006**
            
            **2005**Accounts
                receivables
            
            $
            7,583,000
            
            $
            6,854,000Less:
                allowance for doubtful accounts
            
            
            (799,000
            )
            
            (1,333,000
            )$
            6,784,000
            
            $
            5,521,000


**NOTE
      5 - INVENTORIES**





Inventories
      are valued at the lower of cost or market as determined under the first-in,
      first-out method. Costs include materials, labor and manufacturing overhead.
      Inventories are shown net of applicable reserves and allowances. Inventories
      consist of the following:





**April
                30,**
            
            **October
                31,****2006**
            
            **2005**Rawmaterials
            
            $
            1,668,000
            
            $
            1,468,000Work
                in process
            
            
            74,000
            
            
            45,000Finished
                goods
            
            
            2,167,000
            
            
            2,218,000$
            3,909,000
            
            $
            3,731,000





-11-
 **Back
            to Table of
            Contents**
  **NOTE
      6 - LINE OF CREDIT**





On
      October 5, 2005, the Company entered into a Loan and Security Agreement (the
      “Loan Agreement”) **** with
      Silicon Valley Bank (the “Bank”), for a secured, revolving line of credit of up
      to $5,000,000. The line of credit has a term of one year and includes a letter
      of credit sub-facility. Borrowings under the line of credit are subject to
      a
      borrowing base formula. The Company will pay interest on the borrowings under
      the line of credit at the Bank’s prime rate or, if certain financial tests are
      not satisfied, at the Bank’s prime rate plus 1.5%. The line of credit is secured
      by all of the assets of the Company and is subject to customary financial and
      other covenants, including reporting requirements.





On
      January 12, 2006, the Company, entered into a First Amendment to Loan and
      Security Agreement (the “Amendment”) with the Bank.  The Amendment revised
      certain terms of the Loan Agreement to provide an adjustment to the borrowing
      base formula and to permit liens in favor of a holder of subordinated debt
      that
      are subordinated to the liens of the Bank.  In addition, the Amendment
      decreased the minimum tangible net worth that must be maintained by the Company
      under the Asset Based Terms of the Loan Agreement from $5 million to $1.5
      million and granted the Bank a warrant to purchase 39,683 shares of the
      Company’s common stock at an exercise price of $1.89 per share.  The
      warrant will expire in five years unless previously exercised. The
      Company calculated the fair value of the warrant on the date of grant to be
      $51,000 using the Black-Scholes model incorporating the following
      assumptions:


Stock
                price
            
            $
            1.89Dividend
                yield
            
            
            0
            %Expected
                volatility
            
            
            63
            %Risk-free
                interest rate
            
            
            4.9
            %Expected
                life
            
            
            5
                years





The
      value
      of the warrant is being amortized over the term of the line of credit at $5,100
      per month, and is included in Interest and Other Expense on the Income
      Statement.





**NOTE
      7 - LONG TERM DEBT**





On
      March
      28, 2006, the Company entered into a Loan and Security Agreement (the “Loan
      Agreement”) **** with
      Partners for Growth, LLC (the “Debt Provider”), for a secured, revolving line of
      credit of up to $4,000,000, which will supplement an existing line of credit
      provided by Silicon Valley Bank. The line of credit has a term of eighteen
      months. Borrowings under the line of credit are subject to a borrowing base
      formula. The Company has paid interest on the borrowings under the line of
      credit at prime rate as quoted in the *Wall
      Street Journal,* which on
      April 30, 2006 was 7.75%. Amounts owing under the line of credit are secured
      by
      all of the assets of the Company and are subordinated to amounts owing under
      the
      line of credit with Silicon Valley Bank. The line of credit does not contain
      financial covenants, however the Company is subject to other customary
      covenants, including reporting requirements, and events of default. In
      connection with the Loan Agreement, the Company also granted the Debt Provider
      a
      warrant to purchase 395,000 shares of the Company’s common stock at an exercise
      price of $1.89 per share. The warrant will expire in five years unless
      previously exercised. The
      Company calculated the fair value of the warrant on the date of grant to be
      $475,000 using the Black-Scholes model incorporating the following
      assumptions:


Stock
                price
            
            $
            2.05Dividend
                yield
            
            
            0
            %Expected
                volatility
            
            
            63
            %Risk-free
                interest rate
            
            
            4.9
            %Expected
                life
            
            
            5
                years






-12-
 **Back
          to Table of Contents**


The
      issuance of the warrant has been accounted for as a loan origination fee. As
      such, the value of the warrant has been deferred and is being amortized over
      the
      life of the loan at $26,500 per month and is included in Interest and Other
      Expense on the Income Statement.





**NOTE
      8 - NET LOSS PER SHARE**





Basic
      earnings (loss) per share is computed by dividing the net income (loss) by
      the
      weighted average number of shares outstanding for the period. Diluted earnings
      (loss) per share is computed by dividing the net income (loss) by the sum of
      the
      weighted average number of common shares outstanding for the period plus the
      assumed exercise of all dilutive securities by applying the treasury stock
      method unless such assumed exercises are anti-dilutive. The following table
      sets
      forth the computation of basic and diluted earnings (loss) per
      share:





**Three
                months ended April 30,**
            
            **Six
                months ended April 30,****2006**
            
            **2005**
            
            **2006**
            
            **2005**Net
                loss
            
            $
            (3,695,000
            )
            $
            (3,928,000
            )
            $
            (6,370,000
            )
            $
            (7,578,000
            )Weighted
              average shares outstanding - basic
            
            
            16,988,863
            
            
            16,231,436
            
            
            16,975,087
            
            
            16,287,595Dilutive
              effect of stock options and
              warrants
            
            
            —
            
            
            —
            
            
            —
            
            
            —Weighted
              average shares outstanding
              -diluted
            
            
            16,988,863
            
            
            16,231,436
            
            
            16,975,087
            
            
            16,287,595


Basic
                loss per share
            
            $
            (0.22
            )
            $
            (0.24
            )
            $
            (0.38
            )
            $
            (0.47
            )Diluted
                loss per share
            
            $
            (0.22
            )
            $
            (0.24
            )
            $
            (0.38
            )
            $
            (0.47
            )





Stock
      options to purchase 2,896,940 and 3,044,963 common shares for the three months
      ended April 30, 2006, and 2005, respectively, and 2,576,027 and 3,100,905 common
      shares for the six months ended April 30, 2006 and 2005, respectively, were
      not
      included in the computation of diluted earnings per share because their effect
      would have been anti-dilutive.





**NOTE
      9** - **INTANGIBLE
      ASSETS**





**April
                30, 2006**
            
            **October
                31, 2005****Gross
                Carrying Amount**
            
            **Accumulated
                Amortization**
            
            **Gross
                Carrying Amount**
            
            **Accumulated
                Amortization**Amortizable
                intangible assetsPurchased
                technology
            
            $
            3,129,000
            
            $
            2,673,000
            
            $
            3,129,000
            
            $
            2,622,000Existing
                customer relationships
            
            
            1,770,000
            
            
            495,000
            
            
            1,770,000
            
            
            353,000Trademark
            
            
            1,666,000
            
            
            608,000
            
            
            1,666,000
            
            
            490,000Patents
                and licenses
            
            
            98,000
            
            
            42,000
            
            
            98,000
            
            
            40,000$
            6,663,000
            
            $
            3,818,000
            
            $
            6,663,000
            
            $
            3,505,000


Amortization
      expense was $157,000 and $575,000 for the three months ended April 30, 2006
      and
      2005, respectively, and $314,000 and $1,150,000 for the six months ended April
      30, 2006 and 2005, respectively.




-13-
 **Back
          to Table of Contents**




The
      Company’s current estimate of aggregate amortization expense for subsequent
      years is as follows:





**For
                the Years Ended April 30,**2007
            
            $
            626,0002008
            
            
            626,0002009
            
            
            626,0002010
            
            
            626,0002011
            
            
            341,000$
            2,845,000


**NOTE
      10 - DISCONTINUED OPERATION**





In
      September 2004, the Company shut-down its Theseus operation. Effective with
      the
      fourth quarter of 2004, this segment is reflected as a discontinued operation.
      All prior period results have been restated accordingly, including the
      reallocation of fixed overhead charges to other business segments.





There
      were no revenues or expenses from the discontinued operation in the six months
      ended April 30, 2006 and 2005.





Assets
      and liabilities of the discontinued operations were as follows:




**April
                30,**
            
            **October
                31,****2006**
            
            **2005**Other
                assets
            
            
            16,000
            
            
            16,000Accounts
                payable
            
            
            (3,000
            )
            
            (3,000
            )Accrued
                expenses
            
            
            (269,000
            )
            
            (350,000
            )Net
                assets (liabilities) of discontinued operation
            
            $
            (256,000
            )
            $
            (337,000
            )


When
      reporting the restated prior period results showing the Theseus operation as
      a
      discontinued operation, the Company combined the cash flows attributable to
      Theseus within the operating cash flow category. The following table reports,
      for the last 3 fiscal years, separate totals of operating, investing and
      financing portions of the cash flows attributable to the discontinued
      operation:




**For
                  the Years Ended October 31,****2005**
            
            **2004**
            
            **2003**Net
                cash used in discontinued operating activities
            
            $
            578,000
            
            $
            8,214,000
            
            $
            8,320,000Net
                cash used in discontinued investing activities
            
            
            —
            
            
            179,000
            
            
            310,000Net
                cash used in discontinued financing activities
            
            
            —
            
            
            —
            
            
            —Total
                cash used in discontinued operations
            
            $
            578,000
            
            $
            8,393,000
            
            $
            8,630,000






-14-
 **Back
          to Table of Contents**


**NOTE
      11 - SEGMENT INFORMATION**





The
      Company’s operations are divided into segments based upon a combination of
      factors including: product produced, manufacturing process and management
      oversight.  The Company’s two segments are: IMRT/IGRT and Radiation
      Sources. IMRT/IGRT develops and markets products used during external beam
      radiation therapy for the treatment of cancer.  Radiation Sources develops
      and markets radioisotopic products including brachytherapy seeds and accessories
      used in the treatment of cancer and non-therapeutic products used in medical,
      environmental, research and industrial applications.





The
      Company evaluates performance and allocates resources based upon operating
      results and development milestones. The accounting polices of the reportable
      segments are the same as those described in Note 1 in the summary of significant
      accounting policies. There are no inter-company sales or profits.





The
      Company’s segments are business units that either offer different products or
      are managed separately because they operate with distinct manufacturing and
      development processes.





**Three
                months ended April 30,**
            
            **Six
                months ended April 30,****2006**
            
            **2005**
            
            **2006**
            
            **2005****Revenues**IMRT/IGRT
            
            $
            4,831,000
            
            $
            6,074,000
            
            $
            9,506,000
            
            $
            11,409,000Radiation
                Sources
            
            
            3,226,000
            
            
            3,067,000
            
            
            6,078,000
            
            
            5,896,000$
            8,057,000
            
            $
            9,141,000
            
            $
            15,584,000
            
            $
            17,305,000**Loss
                from Operations**IMRT/IGRT
            
            $
            (1,907,000
            )
            $
            (2,879,000
            )
            $
            (3,358,000
            )
            $
            (5,516,000
            )Radiation
                Sources
            
            
            (1,688,000
            )
            
            (1,104,000
            )
            
            (2,915,000
            )
            
            (2,185,000
            )$
            (3,595,000
            )
            $
            (3,983,000
            )
            $
            (6,273,000
            )
            $
            (7,701,000
            )




**April
                30,**
            
            **October
                31,****2006**
            
            **2005****Goodwill**IMRT/IGRT
            
            $
            2,564,000
            
            $
            2,564,000$
            2,564,000
            
            $
            2,564,000**Total
                assets**IMRT/IGRT
            
            $
            14,529,000
            
            $
            14,899,000Radiation
                Sources
            
            
            7,634,000
            
            
            7,418,000Discontinued
                operation
            
            
            16,000
            
            
            16,000$
            22,179,000
            
            $
            22,333,000






-15-
 **Back
          to Table of Contents**


**NOTE
      12—COMMITMENTS AND CONTINGENCIES**





*Contract
      Commitments*





The
      Company has entered into purchase commitments of $0.1 million to suppliers
      under
      blanket purchase orders.





*Lease
      Commitments*





The
      Company leases facilities and equipment under non-cancelable operating lease
      agreements. Future minimum lease payments are subject to annual adjustment
      for
      increases in the Consumer Price Index. Future minimum annual lease payments
      under all operating leases are as follows:





**For
                the Years Ended April 30,**2007
            
            $
            736,0002008
            
            
            492,0002009
            
            
            492,0002010
            
            
            492,0002011
            
            
            492,000Thereafter
            
            
            901,000$
            3,605,000





*Third
      Party License Agreements*





We
      license from third parties some of the technologies used in our core products.
      The following are the minimum annual royalty amounts under each of the
      agreements:


Lawrence
                Livermore National Laboratory
            
            $
            25,000Wisconsin
                Alumni Research Foundation
            
            
            15,000University
                of Texas
            
            
            50,000National
                Research Council of Canada
            
            
            30,000$
            120,000


*Employment
      Agreements*





The
      Company maintains employment agreements with certain key management. The
      agreements provide for minimum base salaries, eligibility for stock options
      and
      performance bonuses and severance payments.





*Litigation*





In
      December, 2004, an individual plaintiff, Steven Weeks, filed a complaint in
      the
      Coos County Circuit Court of the State of Oregon against Bay Area Health
      District, North American Scientific, Inc., NOMOS




-16-
 **Back
          to Table of Contents**


Corporation
      and Carl Jenson, M.D., alleging the defendants caused Mr. Weeks to receive
      excessive radiation during the course of his IMRT treatment, as a result of
      a
      manufacturing and/or design defect(s) in the Company’s CORVUS and BAT products.
      In September, 2005, prior to the case going to trial, the Company was party
      to a
      settlement agreement and the lawsuit is no longer an ongoing matter. Under
      the
      arrangement, the parties mutually agreed to dismiss all claims and counterclaims
      against each other without admitting any wrongdoing.





In
      November, 2005, the Company was served with a complaint filed in U.S. District
      Court in Hartford, Connecticut by World Wide Medical Technologies (WWMT). WWMT’s
      six count complaint alleges breach of a confidentiality agreement, fraud, patent
      infringement, wrongful interference with contractual relations, violation of
      the
      Connecticut Uniform Trade Secrets Act, and violation of the Connecticut Unfair
      Practices Act. WWMT alleges that the Company fraudulently obtained WWMT’s
      confidential information during negotiations to purchase WWMT in 2004 and that
      once the Company acquired that information, it purportedly learned that Richard
      Terwilliger, (our current Vice President of New Product Development) owned
      certain patent rights and that we began trying to inappropriately gain property
      rights by hiring him away from WWMT. The Company was served with this matter
      at
      approximately the same time Mr. Terwilliger was served with a state court claim
      seeking a preliminary injunction preventing Terwilliger from effectively serving
      as VP of New Product Development at NASI. The Company has agreed to defend
      Mr.
      Terwilliger. We have removed the state court claim against Mr. Terwilliger
      to
      federal court and have had the cases joined. We have also answered both
      complaints and discovery has commenced in each matter, while the parties await
      a
      date from the U.S. District Court for a hearing upon an injunction sought by
      WWMT. The Company denies liability and intends to vigorously defend this case
      as
      it progresses.





On
      April
      20, 2006, a lawsuit captioned *J.P.
      Morgan Trust Company, N.A. v. John Alan Friede, et al.* was
      filed in the U.S. District Court for the Southern District of New York against
      John A. Friede, a current director and stockholder of North American Scientific,
      Inc. (“NASI”), Mr. Friede’s wife, and NOMOS Corporation, a subsidiary of NASI.
      The plaintiff, J.P. Morgan Trust Company, filed the lawsuit in its capacity
      as
      personal representative of the Estate of Evelyn A.J. Hall, Mr. Friede’s deceased
      mother. The complaint asserts claims for reimbursement and contribution,
      constructive fraud, breach of contract and other related claims arising out
      of
      loans made by Mrs. Hall to, or for the benefit of, Mr. and Mrs. Friede and/or
      NOMOS, or acting as an accommodation party in additional loans made to Mr.
      and
      Mrs. Friede by financial institutions that were not subsequently repaid. During
      the time periods alleged in the complaint, Mr. Friede was the Chairman, Chief
      Executive Officer and the largest stockholder of NOMOS. With respect to NOMOS,
      the complaint seeks approximately $5,250,000 principal amount of loans allegedly
      made to and still outstanding and owed by NOMOS, and other related equitable
      remedies plus interest, costs and expenses.





On
      the
      basis of copies of documents that have been made available to us, we believe
      that the claims made against NOMOS in the lawsuit appear to be without merit
      and
      we intend to vigorously defend against them. However, in accordance with the
      indemnification provisions of the merger agreement under which we acquired
      NOMOS
      on May 4, 2004, and the related indemnity escrow agreement, we have made a
      claim
      for indemnification against the escrow to preserve our right of indemnity.
      Under
      these provisions, an indemnifying party will not have any indemnification
      obligations until such time as the aggregate indemnified losses for which we
      are
      entitled to indemnification equals or exceeds $400,000, at which point, the
      indemnifying party will be liable for the full amount of all such indemnified
      losses without regard to the $400,000 basket. As of the date hereof, the
      indemnity escrow account holds approximately $1,225,000 of cash and 526,810
      shares of our common stock. We also intend to review various other legal
      remedies that may be available to us.




The
      Company is also subject to other legal proceedings, claims and litigation
      arising in the ordinary course of business. While the outcome of these matters
      is currently not determinable, management does not expect




-17-
 **Back
          to Table of Contents**


that
      the
      ultimate costs to resolve these matters will have a material adverse effect
      on
      the Company's consolidated financial position, results of operations, or cash
      flows.





**NOTE
      13—STOCKHOLDERS' EQUITY**





*Stock
      Options*





The
      Company's 1996 Stock Option Plan ("1996 Plan"), as amended April 6, 2001,
      provided for the issuance of incentive stock options to employees of the Company
      and non-qualified options to employees, directors and consultants of the Company
      with exercise prices equal to the fair market value of the Company's stock
      on
      the date of grant. Certain options are immediately exercisable while other
      options vest over periods up to four years. The options expire ten years from
      the date of grant. The 1996 Plan provided for the automatic increase on
      January 1 of each year, beginning with calendar year 2002 and continuing
      through calendar year 2004, by a number of shares equal to 3.5% of the total
      number of shares of the Company's Common Stock outstanding on the last trading
      day in the immediately preceding calendar year. In May 2004, the Company’s
      shareholders approved proposals to amend the 1996 Plan to make an additional
      600,000 shares available for issuance under the plan and to permit the issuance
      of 1,362,589 replacement options in connection with the acquisition of NOMOS.
      The 1996 Plan expired on April 1, 2006.





On
      May 3,
      2006, the Company’s shareholders approved the North American Scientific, Inc.
      2006 Stock Plan (“2006 Plan”). Under the 2006 plan, the Company may issue up to
      1,700,000 shares, plus any shares from the 1996 plan that are subsequently
      terminated, expire unexercised or forfeited, to employees of the Company through
      incentive stock options, non-qualified options, stock appreciation rights,
      restricted stock and restricted stock units. The exercise price of the option
      is
      equal to the fair market value of the Company’s stock on the date of the grant.
      At April 30, 2006, no equity awards have been granted under the 2006
      Plan.





In
      March 2003, the Company's shareholders approved the 2003 Non-Employee
      Directors' Equity Compensation Plan ("Directors' Plan"). The Directors' Plan
      supersedes prior provisions for grants of stock options to non-employee
      directors contained in the 1996 Plan. Under the Directors' Plan, the Company
      may
      issue up to 500,000 shares to non-employee directors of the Company through
      non-qualified options or restricted stock. The exercise price of options is
      equal to the fair market value of the Company's stock on the date of grant.
      Options and restricted stock vest equally over a three-year period. The options
      expire ten years from the date of grant. At April 30, 2006, there were 235,000
      shares available for grant under the Directors’ Plan.





At
      April
      30, 2006, a total of 3,735,924 shares of the Company’s common stock were
      reserved for issuance.





The
      following table summarizes stock option activity for both plans:


**Options**
            
            **Options
                Outstanding****Available**
            
            **Number****for
                  Grant**
            
            **Outstanding**
            
            **Exercise
                  Price**Balance
                at October 31, 2003
            
            
            549,188
            
            
            2,678,954
            
            $
            0.03
                - $24.54Granted
            
            
            (306,000
            )
            
            306,000
            
            $
            7.49
                - $10.01Replacement
                options
            
            
            (1,362,589
            )
            
            1,362,589
            
            $
            1.10
                - $4.42Canceled
                or expired
            
            
            375,858
            
            
            (375,858
            )
            $
            1.11
                - $22.11Exercised
            
            
            —
            
            
            (717,864
            )
            $
            1.11
                - $7.94Additional
                shares reserved
            
            
            2,323,285
            
            
            —Balance
                at October 31, 2004
            
            
            1,579,742
            
            
            3,253,821
            
            $
            0.03
                - $24.54Granted
            
            
            (275,000
            )
            
            275,000
            
            $
            2.25
                - $3.66Canceled
                or expired
            
            
            427,699
            
            
            (427,699
            )
            $
            1.11
                - $16.75Exercised
            
            
            —
            
            
            (687,013
            )
            $
            1.11
                - $1.96Balance
                at October 31, 2005
            
            
            1,732,441
            
            
            2,414,109
            
            $
            0.03
                - $24.54Granted
            
            
            (1,303,000
            )
            
            1,303,000
            
            $
            2.23
                - $3.35Canceled
                or expired
            
            
            (194,441
            )
            
            (215,794
            )
            $
            1.12
                - $16.75Exercised
            
            
            —
            
            
            (391
            )
            $
            1.12Balance
                at April 30, 2006
            
            
            235,000
            
            
            3,500,924
            
            $
            0.70
                - $24.54






-18-
 **Back
          to Table of Contents**


There
      were 1,764,650, 1,873,220 and 1,591,598 options exercisable with weighted
      average exercise prices of $8.85, $8.79 and $9.31 at April 30, 2006,
      October 31, 2005 and 2004, respectively.





The
      following table summarizes options outstanding at April 30, 2006 and the related
      weighted average exercise price and remaining contractual life
      information:




**Employee
                Options Outstanding**
            
            
            **Employee
                Options Exercisable****Range
                of**
              **Exercise
                Prices**
            
            
            **Shares**
            
            
            **Weighted
                Avg.**
              **Remaining**
              **Contractual**
              **Life
                (Years)**
            
            
            **Weighted**
              **Avg.**
              **Exercise**
              **Price**
            
            
            **Shares**
            
            
            **Weighted**
              **Avg.**
              **Exercise**
              **Price**$
                0.70 - $2.23
            
            
            925,852
            
            
            5.61
            
            $
            1.94
            
            
            270,207
            
            $
            0.85$3.18
                - $3.35
            
            
            880,500
            
            
            8.24
            
            
            6.79
            
            
            —
            
            
            —$3.94
                - $7.60
            
            
            728,595
            
            
            5.80
            
            
            8.07
            
            
            625,464
            
            
            7.93$7.94
                - $11.81
            
            
            711,467
            
            
            5.74
            
            
            10.82
            
            
            614,469
            
            
            10.86$12.89
                - $24.54
            
            
            254,510
            
            
            3.56
            
            
            19.98
            
            
            254,510
            
            
            19.983,500,924
            
            
            6.19
            
            $
            6.17
            
            
            1,764,650
            
            $
            8.85


The
      average fair value for accounting purposes of options granted was $1.08, $2.47
      and $5.19 for the six months ended April 30, 2006 and the years ended
      October 31, 2005 and 2004, respectively.





The
      following table summarizes the weighted average price, weighted average
      remaining contractual life and intrinsic value for granted and exercisable
      options outstanding as of April 30, 2006 and October 31, 2005:




**Number
                  of**
                **Shares**
            
            **Weighted**
                **Average**
                **Exercise
                  Price**
            
            **Weighted
                  Avg.**
                **Remaining**
                **Contractual**
                **Life
                  (Years)**
            
            **Intrinsic
                  Value***As
                of October 31, 2005:*Employee
                Options Outstanding
            
            
            2,414,109
            
            $
            8.13
            
            
            6.09
            
            $
            464,000Employee
                Options Expected to Vest
            
            
            540,889
            
            $
            5.67
            
            
            8.91
            
            $
            4,000Employee
                Options Exercisable
            
            
            1,873,220
            
            $
            8.79
            
            
            5.25
            
            $
            460,000*As
                of April 30, 2006*Employee
                Options Outstanding
            
            
            3,500,924
            
            $
            6.17
            
            
            6.19
            
            $
            358,000Employee
                Options Expected to Vest
            
            
            1,736,274
            
            $
            2.66
            
            
            6.89
            
            $
            -0-Employee
                Options Exercisable
            
            
            1,764,650
            
            $
            8.85
            
            
            4.73
            
            $
            358,000






-19-
 **Back
          to Table of Contents**




*Fair
      Value Disclosures*





The
      Company calculated the fair value of each option grant on the respective date
      of
      grant using the Black-Scholes option-pricing model as prescribed by
      SFAS 123 using the following assumptions:




**Six
                Months Ended**
              **April
                30**
            
            **Year
                Ended**
              **October
                31,****2006**
            
            **2005**
            
            **2004**Dividend
                yield
            
            
            0
            %
            
            0
            %
            
            0
            %Expected
                volatility
            
            
            63
            %
            
            82
            %
            
            74
            %Risk-free
                interest rate
            
            
            4.9
            %
            
            3.9
            %
            
            3.3
            %Expected
                life
            
            
            5
                years
            
            
            5
                years
            
            
            5
                years


*Employee
      Stock Purchase Plan*





The
      Company has an Employee Stock Purchase Plan ("the ESPP") under which 300,000
      shares of the Company's common stock are reserved for issuance. Eligible
      employees may authorize payroll deductions of up to 15% of their salary to
      purchase shares of the Company's common stock at a discount of up to 15% of
      the
      market value at certain plan-defined dates. In the six months ended April 30,
      2006 and the years ended October 31, 2005 and 2004, the shares issued under
      the
      ESPP were 39,834, 59,742 and 24,285 shares, respectively. At April 30, 2006,
      130,494 shares were available for issuance under the ESPP.





**Item
      2. Management’s Discussion and Analysis of Financial Condition
      and Results of Operations**





The
      following discussion and analysis provides information, which our management
      believes is relevant to an assessment and understanding of our financial
      condition and results of operations. The discussion should be read in
      conjunction with the Consolidated Financial Statements contained herein and
      the
      notes thereto. Certain statements contained in this quarterly report on
      Form 10-Q, including, without limitation, statements containing the words
“believes”, “anticipates”, “estimates”, “expects”, “projections”, and words of
      similar import are forward looking as that term is defined by: (i) the
      Private Securities Litigation Reform Act of 1995 (the "1995 Act") and
      (ii) releases issued by the Securities and Exchange Commission (“SEC”).
      These statements are being made pursuant to the provisions of the 1995 Act
      and
      with the intention of obtaining the benefits of the "Safe Harbor" provisions
      of
      the 1995 Act. We caution that any forward looking statements made herein are
      not
      guarantees of future performance and that actual results may differ materially
      from those in such forward looking statements as a result of various factors,
      including, but not limited to, any risks detailed herein or detailed from time
      to time in our other filings with
      the
      SEC including our most recent annual report on Form 10-K, as amended. We
      are not undertaking any obligation to update publicly any forward-looking
      statements. Readers should not place undue reliance on these forward-looking
      statements.





**Subsequent
      Events**





On
      June
      7, 2006, the Company closed an approximately $24 million private placement
      of
      shares of its common stock and the concurrent issuance of warrants for the
      purchase of additional shares of its common stock. Net proceeds from the
      financing will be used for new product development, including the Company’s
      breast brachytherapy product, and for working capital.





At
      the
      closing, the investors received 12,291,934 shares of the Company’s common stock
      at a purchase price of $1.95 per share as well as warrants to purchase an
      additional 6,145,967 shares of the Company’s common stock at an exercise price
      of $2.08 per share, which are exercisable beginning 180 days after the date
      of
      closing until 7 years after the date of closing.




-20-
 **Back
          to Table of Contents**





The
      securities sold in this private placement have not been registered under the
      Securities Act of 1933, as amended, and may not be offered or sold in the United
      States in the absence of an effective registration statement or exemption from
      registration requirements. The Company agreed to file a registration statement
      after the closing of the transaction for purposes of registering the resale
      of
      the shares of common stock issued in the private placement and the shares of
      common stock issuable upon exercise of the warrants.





**Overview**





We
      manufacture, market and sell products for the radiation oncology community,
      including intensity modulated and image guided radiation therapy products and
      services, as well as brachytherapy seeds used in the treatment of prostate
      cancer. Our business is organized into two operating segments: IMRT/IGRT and
      Radiation Sources.





IMRT/IGRT
      develops and markets intensity modulated radiation therapy (“IMRT”) and image
      guided radiation therapy (“IGRT”) products used in external beam radiation
      therapy for the treatment of disease. Radiation Sources develops and markets
      radioisotopic products including brachytherapy seeds, accessories and
      calibration sources used in the treatment of disease and used in medical,
      environmental, research and industrial applications. In May 2004, we acquired
      NOMOS Corporation (“NOMOS”). NOMOS was a privately held developer, manufacturer,
      and marketer of IMRT and IGRT products and services. We manage this business
      as
      our IMRT/IGRT operating segment.





Especially
      in view of our recent private placement of common stock, based on our current
      operating plans, we believe that the existing cash resources, cash forecasted
      by
      our plans to be generated by operations, the issuance of our common stock and/or
      debt, as well as our anticipated and available lines of credit, will be
      sufficient to meet working capital and capital requirements through at least
      the
      next twelve months.  Also, our plans to attain profitability and generate
      additional cash flows include increasing revenues from existing and new products
      and services and a focus on cost control.  There is no assurance that we
      will be successful with these plans.  However, if events and circumstances
      occur such that we do not meet our current operating plans as expected, and
      we
      are unable to raise additional debt or equity financing, we may be required
      to
      further reduce expenses or take other steps which could have a material adverse
      effect on our future performance, including but not limited to, the premature
      sale of some or all of the Company’s assets or product lines on undesirable
      terms, merger with or acquisition by another company on unsatisfactory terms,
      or
      the cessation of operations.





**Results
      of Operations**





**Three
      Months Ended April 30, 2006 Compared to Three Months Ended April 30,
      2005**





**Revenue** .
      Revenue
      decreased $1.0 million, or 12%, to $8.1 million for the three months ended
      April
      30, 2006, from $9.1 million for the three months ended April 30, 2005. The
      decrease in revenue during the quarter ended April 30, 2006, is primarily
      attributable to a decline in the volume of maintenance and warranty agreements
      for IMRT/IGRT products ($1.1 million) partially offset by an increase in
      Radiation Sources Revenues ($0.2 million).





Product
      revenue of $5.8 million for the three months ended April 30, 2006 is unchanged
      from $5.8 million for the three months ended April 30, 2005. Radiation Sources
      product revenue increased $0.2 million for the three months ended April 30,
      2006
      primarily due to a product mix shift toward the higher priced palladium seeds
      and an increase in volume for non-therapeutic products. This was offset by
      a
      decline in unit volume for IMRT/IGRT products.




-21-
 **Back
          to Table of Contents**





Service
      revenue decreased $1.1 million, or 33%, to $2.2 million for the three months
      ended April 30, 2006, from $3.3 million for the three months ended April 30,
      2005 due to a decline in the number of maintenance agreements for IMRT/IGRT
      products.





**Gross
      profit** .
      Gross
      profit decreased $0.7 million, or 20%, to $2.9 million for the three months
      ended April 30, 2006, from $3.6 million for the three months ended April 30,
      2005. The decrease in gross profit is attributed to declining service revenues
      partially offset by lower product costs in our IMRT/IGRT business ($0.5 million)
      and a product mix shift toward lower margin palladium seeds and start-up costs
      of our in-house stranding operations in our Radiation Sources business ($0.2
      million). Gross profit as a percentage of revenues decreased from 40% to 36%
      during this period.





Gross
      profit for the three months ended April 30, 2006 consists of $2.1 million,
      or
      44%, of revenue from our IMRT/IGRT business and $0.8 million, or 25% of revenue
      from our Radiation Sources business.





**Selling
      Expenses** .
      Selling
      expenses include salaries, commissions and other related costs associated with
      our sales and marketing personnel and advertising, trade shows and other
      promotional programs. Selling expenses increased $0.1 million, or 8%, to $2.3
      million for the three months ended April 30, 2006, from $2.2 million for the
      three months ended April 30, 2005. The increase in selling expenses is primarily
      attributed to severance costs related to a restructuring of the sales
      force.





**General
      and administrative expenses** .
      General
      and administrative (“G&A”) expenses include salaries and other related costs
      associated with finance, executive, human resources and information technology
      personnel and other administrative costs. G&A expenses decreased $0.7
      million, or 20%, to $2.6 million for the three months ended April 30, 2006,
      from
      $3.3 million for the three months ended April 30, 2005. The decrease is
      primarily attributed to a $0.5 million reduction in personnel expenses and
      a
      $0.4 million reduction in bad debt expense being partially offset by $0.2
      million in stock compensation expense as a result of the implementation of
      SFAS
      123R which requires the expensing of stock options.





**Research
      and development** .
      Research and development (“R&D”) expenses include salaries and other related
      costs associated with product development, third party development costs,
      overhead costs and material used in development of prototypes. Our R&D costs
      decreased $0.2 million, or 13%, to $1.4 million for the three months ended
      April
      30, 2006, from $1.6 million for the three months ended April 30, 2005. The
      decrease is primarily attributed to $0.4 million reduction in personnel expenses
      and project expenditures in our IMRT/IGRT business offset by a $0.2 million
      increase in our Radiation Sources segment due to project expenditures relating
      to in-house stranding and breast brachytherapy.


**Amortization
      of intangible assets** .
      Amortization of intangible assets decreased $0.4 million, or 73%, to $0.2
      million for the three months ended April 30, 2006 from $0.6 million for the
      three months ended April 30, 2005. The decrease is attributed to the writedown
      of certain intangible assets in the fourth quarter of 2005.





**Interest
      and other income, net.** Interest
      expense was $100,000 for the three months ended April 30, 2006, compared to
      interest income of $55,000 for the three months ended April 30, 2005. The
      interest expense in fiscal 2006 resulted from the short-term and long-term
      debt
      and amortization of warrants, and the interest income in fiscal 2005 was due
      to
      a portfolio of marketable securities.




-22-
 **Back
          to Table of Contents**





**Six
      Months Ended April 30, 2006 Compared to Six Months Ended April 30,
      2005**





**Revenue** .
      Revenue
      decreased $1.7 million, or 10%, to $15.6 million for the six months ended April
      30, 2006, from $17.3 million for the six months ended April 30, 2005. The
      decrease in revenue during the six months ended April 30, 2006, is due to
      declines in IMRT/IGRT product revenue ($0.4 million) and IMRT/IGRT service
      revenue ($1.5 million) partially offset by an increase in our Radiation Sources
      revenue ($0.2 million).





Product
      revenue decreased $0.2 million, or 2%, to $11.0 million for the six months
      ended
      April 30, 2006, from $11.2 million for the six months ended April 30, 2005.
      The
      decrease in product revenue during the six months ended April 30, 2006, is
      largely due to a decline in unit sales of IMRT/IGRT products ($0.4 million)
      partially offset by an increase in Radiation Sources ($0.2 million).





Service
      revenue decreased $1.5 million, or 25%, to $4.6 million for the six months
      ended
      April 30, 2006, from $6.1 million for the six months ended April 30, 2005 due
      to
      a decline in the number of maintenance agreements for IMRT/IGRT products.





**Gross
      profit** .
      Gross
      profit decreased $0.8 million, or 12%, to $5.8 million for the six months ended
      April 30, 2006, from $6.6 million for the six months ended April 30, 2005.
      The
      decrease in gross profit is attributed to declines in the product and service
      revenue in our IMRT/IGRT business ($0.6 million), and a product mix shift to
      lower margin palladium seeds and start-up costs of our in-house stranding
      operations in our Radiation Sources business ($0.2 million). Gross profit as
      a
      percentage of revenues decreased from 38% to 37% during this period.





Gross
      profit for the six months ended April 30, 2006 consists of $4.2 million, or
      45%
      of revenue from our IMRT/IGRT business, and $1.5 million, or 26% of revenue
      from
      our Radiation Sources business.





**Selling
      Expenses** .
      Selling
      expenses include salaries, commissions and other related costs associated with
      our sales and marketing personnel and advertising, trade shows and other
      promotional programs. Selling expenses decreased $0.1 million, or 3%, to $4.2
      million for the six months ended April 30, 2006, from $4.3 million for the
      six
      months ended April 30, 2005. The decrease in selling expenses is primarily
      attributed to reduced sales meeting expenses during the six months ended April
      30, 2006.





**General
      and administrative expenses** .
      General
      and administrative (“G&A”) expenses include salaries and other related costs
      associated with finance, executive, human resources and information technology
      personnel and other administrative costs. G&A expenses decreased $0.8
      million, or 14%, to $4.8 million for the six months ended April 30, 2006, from
      $5.6 million for the six months ended April 30, 2005. The decrease is primarily
      attributed to a $0.7 million reduction in personnel expenses, $0.3 million
      reduction in bad debt expense and $0.2 million reduction in professional fees
      being partially offset by $0.5 million in stock
      compensation expense as a result of the implementation of SFAS 123R which
      requires the expensing of stock options.




**Research
      and development** .
      Research and development (“R&D”) expenses include salaries and other related
      costs associated with product development, third party development costs,
      overhead costs and material used in development of prototypes. Our R&D costs
      decreased $0.5 million, or 16%, to $2.7 million for the six months ended April
      30, 2006, from $3.3 million for the six months ended April 30, 2005. The
      decrease is primarily attributed to $0.7 million reduction in personnel expenses
      and project expenditures in our IMRT/IGRT business partially offset by a $0.2
      million increase in our Radiation Sources segment due to project expenditures
      relating to in-house stranding and breast brachytherapy.




-23-
 **Back
          to Table of Contents**





**Amortization
      of intangible assets** .
      Amortization of intangible assets decreased $0.8 million, or 73%, to $0.3
      million for the six months ended April 30, 2006 from $1.1 million for the six
      months ended April 30, 2005. The decrease is attributed to the writedown of
      certain intangible assets in the fourth quarter of 2005.





**Interest
      and other income, net.** Interest
      expense was $97,000 for the six months ended April 30, 2006, compared to
      interest income of $124,000 income for the six months ended April 30, 2005.
      The
      interest expense in fiscal 2006 resulted from the short-term and long-term
      debt
      and amortization of warrants, and the interest income in fiscal 2005 was due
      to
      a portfolio of marketable securities.





**Liquidity
      and Capital Resources**





To
      date,
      our short-term liquidity needs have generally consisted of working capital
      to
      fund our ongoing operations and to finance growth in inventories, trade accounts
      receivable, new product research and development, capital expenditures,
      acquisitions and strategic investments in related businesses.  We have
      satisfied these needs primarily through a combination of cash generated by
      operations, public offerings, private placements of our common stock and
      issuance of debt.  We expect that we will be able to satisfy our
      longer term liquidity needs for research and development, capital expenditures,
      and acquisitions through a combination of cash generated by operations, public
      offerings, private placements of our common stock, and issuance of
      debt.





The
      accompanying financial statements have been prepared on a going concern basis,
      which contemplates the realization of assets and liquidation of liabilities
      in
      the normal course of business. However, the Company has continued to incur
      substantial net losses and used substantial amounts of cash. As of April 30,
      2006, the Company has an accumulated deficit of $116.7 million, cash and cash
      equivalents of $1.8 million, $3.3 million of short-term debt and $3.0 million
      of
      long-term debt.





Especially
      in view of our recent private placement of common stock, based on our current
      operating plans, we believe that the existing cash resources, cash forecasted
      by
      our plans to be generated by operations, the issuance of our common stock and/or
      debt, as well as our anticipated and available lines of credit, will be
      sufficient to meet working capital and capital requirements through at least
      the
      next twelve months.  Also, our plans to attain profitability and generate
      additional cash flows include increasing revenues from existing and new products
      and services and a focus on cost control.  There is no assurance that we
      will be successful with these plans.  However, if events and circumstances
      occur such that we do not meet our current operating plans as expected, and
      we
      are unable to raise additional debt or equity financing, we may be required
      to
      further reduce expenses or take other steps which could have a material adverse
      effect on our future performance, including but not limited to, the premature
      sale of some or all of the Company’s assets or product lines on undesirable
      terms, merger with or acquisition by another company on unsatisfactory terms,
      or
      the cessation of operations.


At
      April
      30, 2006, we had cash, cash equivalents, and investments in marketable
      securities aggregating approximately $1.8 million, a decrease of approximately
      $1.8 million from $3.6 million at October 31, 2005. The decrease was primarily
      attributed to $8.0 million used in continuing operations, $0.1 million used
      in
      our discontinued operation and $0.2 million used for capital expenditures,
      partially offset by a $6.3 million drawdown on the line of credit and long-term
      debt and $0.1 million in cash received from the exercise of stock options and
      the employee stock purchase plan.





Cash
      flows used in operating activities decreased $0.5 million or 6% to $8.1 million
      for the six months ended April 30, 2006 from $8.6 million for the six months
      ended April 30, 2005. The decrease in cash used in operating activities is
      primarily attributable to a decrease in our net loss ($1.2 million), a lesser
      change in deferred revenue ($0.9 million) and a reduction in cash used in
      discontinued operations ($0.5 million) partially offset by an increase in
      accounts receivable ($1.4 million) and inventory ($1.0 million). We expect
      that
      cash used in operating activities may fluctuate in future periods as a result
      of
      a number of factors, including fluctuations in our operating results, accounts
      receivable collections, inventory management, research and development expenses,
      and the timing of payments.




-24-
 **Back
          to Table of Contents**





Cash
      flows provided by investing activities decreased $5.5 million or 87% to $0.8
      million for the six months ended April 30, 2006, from $6.3 million for the
      six
      months ended April 30, 2005. The decrease is entirely attributable to having
      drawn down our balance of marketable securities prior to the end of FY05 to
      fund
      operations.





Cash
      provided by financing activities increased $6.2 million to $6.4 million for
      the
      six months ended April 30, 2006, from $0.2 million for the six months ended
      April 30, 2005. The increase reflects a drawdown in our line of credit ($3.3
      million) and a drawdown in our long-term debt facility ($3.0 million) partially
      offset by a reduction in proceeds from the exercise of employee stock
      options.





We
      have
      $3.6 million in operating lease obligations for facilities and equipment under
      non-cancelable operating lease agreements. We have also entered into purchase
      commitments to suppliers under blanket purchase orders in the amount of $0.1
      million.





**Critical
      Accounting Policies**





The
      preparation of financial statements and related disclosures in conformity with
      accounting principles generally accepted in the United States of America
      requires management to make judgments, assumptions and estimates that affect
      the
      amounts reported in the Consolidated Financial Statements included in the
      Company’s Form 10-K for the year ended October 31, 2005, and accompanying notes.
      Note 1 to the Consolidated Financial Statements describes the significant
      accounting policies and methods used in the preparation of the Consolidated
      Financial Statements. Estimates are used for, but not limited to, the accounting
      for revenue recognition, allowance for doubtful accounts, goodwill and
      long-lived asset impairments, loss contingencies, and taxes. Estimates and
      assumptions about future events and their effects cannot be determined with
      certainty. We base our estimates on historical experience and on various other
      assumptions believed to be applicable and reasonable under the circumstances.
      These estimates may change as new events occur, as additional information is
      obtained and as our operating environment changes. These changes have
      historically been minor and have been included in the consolidated financial
      statements as soon as they became known. The following critical accounting
      policies are impacted significantly by judgments, assumptions and estimates
      used
      in the preparation of the Consolidated Financial Statements and actual results
      could differ materially from the amounts reported based on these
      policies.





*Revenue
      Recognition*




The
      Company sells products and services for radiation therapy treatment of cancer,
      including intensity modulated radiation therapy (“IMRT”), image guided radiation
      therapy (“IGRT”), as well as brachytherapy. Product revenue consists of
      brachytherapy seeds and accessories, non-therapeutic sources, and certain IMRT
      hardware devices, including our MiMIC and Crane products. Software revenues
      consist of IMRT treatment planning software, including Corvus, Peregrine and
      Peacock, and our IGRT products. Service revenue consists of warranty revenue
      and
      maintenance service agreements.




*Product
      revenue*




We
      apply
      the provisions of SEC Staff Accounting Bulletin (“SAB”) No. 104, “Revenue
      Recognition” for the sale of non-software products.  SAB No. 104 which
      supersedes SAB No. 101, “Revenue Recognition in Financial Statements”, provides
      guidance on the recognition, presentation and disclosure of revenue in financial
      statements.  SAB No. 104 outlines the basic criteria that must be met to
      recognize revenue and provides guidance for the disclosure of revenue
      recognition policies.  In general, we recognize revenue related to product
      sales when (i) persuasive evidence of an arrangement exists, (ii) delivery
      has
      occurred, (iii) the fee is fixed or determinable, and (iv) collectibility is
      reasonably assured.




-25-
 **Back
          to Table of Contents**




*Software
      revenue*




Our
      software product revenue is generated from the sale of advanced medical
      equipment products. The software element of our products is deemed an essential
      element of the functionality of the product. Maintenance and support are
      provided with the initial product sale for a twelve month period. The
      maintenance and support is renewable annually or longer, at the customer’s
      discretion.




We
      recognize software revenue in accordance with the provisions of Statement of
      Position 97-2 (“SOP 97-2”), “Software Revenue Recognition”, as amended by
      Statement of Position 98-9 (“SOP 98-9”), “Modification of SOP 97-2, Software
      Revenue Recognition, with respect to Certain Transactions”.  Under the
      provisions of SOP 97-2, we recognize software revenue upon delivery and
      acceptance, provided all significant obligations have been met, persuasive
      evidence of an arrangement exists, fees are fixed or determinable, collection
      is
      probable, and we are not involved in providing services that are essential
      to
      the functionality of the product.




Our
      software sales are generally multiple element arrangements, which could include
      the product, first year annual maintenance and support, and training and
      installation.  Revenues from the multiple element arrangements are
      allocated to each element based on the relative fair value of the
      elements.  If the fair value of the element exists, the determination is
      based on vendor specific objective evidence.  If such evidence of fair
      value for each element of the arrangement does not exist, all revenue from
      the
      arrangement is deferred until such time that evidence of fair value of each
      element does exist or until all elements of the arrangement are delivered. 
If in a multiple element arrangement, fair value does not exist for one or
      more
      of the undelivered elements, the residual method of accounting is applied. 
Under the residual method, the fair value of the undelivered elements is
      deferred, and the remaining portion of the arrangement fee is recognized as
      revenue.




*Service
      revenue*




Service
      revenues are derived mainly from maintenance and support contracts and are
      recognized on a straight-line basis over the term of the contract. Payments
      for
      maintenance revenues are normally received in advance and are nonrefundable.




*Allowance
      for Doubtful Accounts and Sales Returns*





The
      allowance for doubtful accounts is based on our assessment of the collectibility
      of specific customer accounts and the aging of the accounts receivable. We
      regularly review the allowance by considering factors
      such as historical experience, age of the accounts receivable balances and
      current economic conditions that may affect a customer's ability to pay. If
      there was a deterioration of a major customer's credit worthiness or actual
      defaults are higher than our historical experience, our estimates of the
      recoverability of amounts due us could be overstated which could have an adverse
      impact on our financial results.





A
      reserve
      for sales returns is established based on historical trends in product return
      rates and is recorded as a reduction of our accounts receivable. If the actual
      future returns were to deviate from the historical data on which the reserve
      had
      been established, our revenue could be adversely affected. To date, product
      returns have not been considered material to our results of
      operations.




-26-
 **Back
          to Table of Contents**





*Inventory
      Reserves*





Inventories
      are valued at the lower of cost or market as determined under the first-in,
      first-out method. Costs include materials, labor and manufacturing
      overhead.





The
      Company's Radiation Sources products are subject to shelf-life expiration
      periods, which are carefully monitored by the Company. Provision is made for
      inventory items which may not be sold because of expiring dates. The Company
      routinely reviews other inventories for evidence of impairment of value and
      makes provision as such impairments are identified.





*Goodwill
      and Other Intangible Assets*





SFAS
      142,
      Goodwill and Other Intangible Assets, requires that goodwill be tested for
      impairment at the reporting unit level (operating segment level or one level
      below an operating segment) on an annual basis (August 31st) and between annual
      tests if an event occurs or circumstances change that would more likely than
      not
      reduce the fair value of a reporting unit below its carrying value. These events
      or circumstances could include a significant change in the business climate,
      legal factors, operating performance indicators, competition, sale or
      disposition of a significant portion of a reporting unit. Application of the
      goodwill impairment test requires management to make various judgments,
      including the identification of reporting units, assignment of assets and
      liabilities to reporting units, assignment of goodwill to reporting units,
      and
      determination of the fair value of each reporting unit. The fair value of each
      reporting unit is estimated using a discounted cash flow methodology. This
      requires significant judgments including estimation of future cash flows, which
      is dependent on internal forecasts, estimation of the long-term rate of growth
      for our business, the useful life over which cash flows will occur, and
      determination of our weighted average cost of capital. Changes in these
      estimates and assumptions could materially affect the determination of fair
      value and/or goodwill impairment for each reporting unit.




*Research
      and Development Costs*





We
      account for research and development costs in accordance with several accounting
      pronouncements, including SFAS 2, Accounting for Research and Development Costs,
      and SFAS 86, Accounting for the Costs of Computer Software to be Sold, Leased,
      or Otherwise Marketed. SFAS 86 specifies that costs incurred internally in
      researching and developing a computer software product should be charged to
      expense until technological feasibility has been established for the product.
      Once technological feasibility is established, all software costs should be
      capitalized until the product is available for general release to customers.
      Judgment is required in determining when technological feasibility of a product
      is established. We have determined that technological feasibility for our
      software products is reached shortly before the products are released to
      manufacturing. Costs incurred after technological feasibility is established
      are
      not material, and accordingly, we expense all research and development costs
      when incurred.


*Loss
      Contingencies*





We
      record
      liabilities related to pending litigation when an unfavorable outcome is
      probable and we can reasonably estimate the amount of the loss. We are subject
      to various legal proceedings and claims, either asserted or unasserted, that
      arise in the ordinary course of business. We evaluate, among other factors,
      the
      degree of probability of an unfavorable outcome and an estimate of the amount
      of
      the loss. Significant judgment is required in both the determination of the
      probability and as to whether an exposure can be reasonably estimated. When
      we
      determine that it is probable that a loss has been incurred, the effect is
      recorded promptly in the consolidated financial statements. Although the outcome
      of these claims cannot be predicted with certainty, we do not believe that
      any
      of our existing legal matters will have a material adverse effect on our
      financial condition or results of operations.




-27-
 **Back
          to Table of Contents**





*Income
      Taxes*





We
      account for income taxes using the liability method. Deferred taxes are
      determined based on the differences between the financial statement and tax
      bases of assets and liabilities, using enacted tax rates in effect for the
      year
      in which the differences are expected to reverse. Valuation allowances are
      established when necessary to reduce deferred tax assets to the amounts expected
      to be realized. In addition, we are subject to examination of our income tax
      returns by the Internal Revenue Service and other tax authorities. We regularly
      assess the likelihood of adverse outcomes resulting from these
      examinations.





**Recent
      Accounting Pronouncements**





In
      February 2006, the FASB issued SFAS No. 155, “Accounting for Certain Hybrid
      Financial Instruments” (“SFAS 155”), which amends SFAS No. 133, “Accounting for
      Derivatives Instruments and Hedging Activities” (“SFAS 133”) and SFAS No. 140,
“Accounting for Transfers and Servicing of Financial Assets and Extinguishment
      of Liabilities” (“SFAS 140).  SFAS 155 amends SFAS 133 to narrow the scope
      exception for interest-only and principal-only strips on debt instruments to
      include only such strips representing rights to receive a specified portion
      of
      the contractual interest or principle cash flows.  SFAS 155 also amends
      SFAS 140 to allow qualifying special-purpose entities to hold a passive
      derivative financial instrument pertaining to beneficial interests that itself
      is a derivative instruments. We
      are
      currently evaluating the impact this new Standard, but believe that it will
      not
      have a material impact on our financial position, results of operations or
      cash
      flows.





In
      March
      2006, the FASB issued SFAS No. 156, “ Accounting
      for Servicing of Financial Assets” (“SFAS NO. 156”), which provides an approach
      to simplify efforts to obtain hedge-like (offset) accounting. This Statement
      amends FASB Statement No. 140, “Accounting for Transfers and Servicing of
      Financial Assets and Extinguishments of Liabilities”, with respect to the
      accounting for separately recognized servicing assets and servicing liabilities.
      The Statement (1) requires an entity to recognize a servicing asset or servicing
      liability each time it undertakes an obligation to service a financial asset
      by
      entering into a servicing contract in certain situations; (2) requires that
      a
      separately recognized servicing asset or servicing liability be initially
      measured at fair value, if practicable; (3) permits an entity to choose either
      the amortization method or the fair value method for subsequent measurement
      for
      each class of separately recognized servicing assets or servicing liabilities;
      (4) permits at initial adoption a one-time reclassification of
      available-for-sale securities to trading securities by an entity with recognized
      servicing rights, provided the securities reclassified offset the entity’s
      exposure to changes in the fair value of the servicing assets or liabilities;
      and (5) requires separate presentation of servicing assets and servicing
      liabilities subsequently measured at fair value in the balance sheet and
      additional disclosures for all separately recognized servicing assets and
      servicing liabilities. SFAS No. 156 is effective for all separately recognized
      servicing assets and liabilities as of the beginning of an entity’s fiscal year
      that begins after September 15, 2006, with earlier adoption permitted in certain
      circumstances. The Statement also describes the manner in which it should be
      initially applied. The Company does not believe
      that SFAS No. 156 will have a material impact on its financial position, results
      of operations or cash flows.




**Item
      3.****Quantitative
      and Qualitative Disclosures about Market Risk**




Information
      about market risks for the three and six months ended April 30, 2006, does
      not
      differ materially from that discussed under Item 7A of our Annual Report on
      Form
      10-K for the fiscal year ended October 31, 2005.




-28-
 **Back
          to Table of Contents**





**Item
      4.****Controls
      and Procedures**




(a)
      Evaluation of Disclosure Controls and Procedures





As
      required by Rule 13a-15(b) under the Securities and Exchange Act of 1934
      (the “Exchange Act”), we have carried out an evaluation, under the supervision
      and with the participation of our management, including our Chief Executive
      Officer (“CEO”) and our Chief Financial Officer (“CFO”), of the effectiveness,
      as of the end of the fiscal quarter covered by this report, of the design and
      operation of our “disclosure controls and procedures” as defined in
      Rule 13a-15(e) promulgated by the SEC under the Exchange Act. Based upon
      that evaluation, our CEO and our CFO concluded that our disclosure controls
      and
      procedures, as of the end of such fiscal quarter, were adequate and effective
      to
      ensure that information required to be disclosed by us in the reports that
      we
      file or submit under the Exchange Act is recorded, processed, summarized and
      reported within the time periods specified in the Commission’s rules and forms
      and that such information is accumulated and communicated to our management,
      including our CEO and CFO, as appropriate to all timely decisions regarding
      required disclosure.





(b)
      Changes in Internal Controls





There
      has
      been no change in our internal control over financial reporting during the
      quarter ended April 30, 2006, that has materially affected or is reasonably
      like
      to materially affect our internal control over financial reporting.





**PART
      II - OTHER INFORMATION**





**Item
      1. Legal Proceedings**





On
      April
      20, 2006, a lawsuit captioned *J.P.
      Morgan Trust Company, N.A. v. John Alan Friede, et al.* was
      filed in the U.S. District Court for the Southern District of New York against
      John A. Friede, a current director and stockholder of North American Scientific,
      Inc. (“NASI”), Mr. Friede’s wife, and NOMOS Corporation, a subsidiary of NASI.
      The plaintiff, J.P. Morgan Trust Company, filed the lawsuit in its capacity
      as
      personal representative of the Estate of Evelyn A.J. Hall, Mr. Friede’s deceased
      mother. The complaint asserts claims for reimbursement and contribution,
      constructive fraud, breach of contract and other related claims arising out
      of
      loans made by Mrs. Hall to, or for the benefit of, Mr. and Mrs. Friede and/or
      NOMOS, or acting as an accommodation party in additional loans made to Mr.
      and
      Mrs. Friede by financial institutions that were not subsequently repaid. During
      the time periods alleged in the complaint, Mr. Friede was the Chairman, Chief
      Executive Officer and the largest stockholder of NOMOS. With respect to NOMOS,
      the complaint seeks approximately $5,250,000 principal amount of loans allegedly
      made to and still outstanding and owed by NOMOS, and other related equitable
      remedies plus interest, costs and expenses.





On
      the
      basis of copies of documents that have been made available to us, we believe
      that the claims made against NOMOS in the lawsuit appear to be without merit
      and
      we intend to vigorously defend against them.
      However, in accordance with the indemnification provisions of the merger
      agreement under which we acquired NOMOS on May 4, 2004, and the related
      indemnity escrow agreement, we intend to make a claim for indemnification
      against the escrow to preserve our right of indemnity. Under these provisions,
      an indemnifying party will not have any indemnification obligations until such
      time as the aggregate indemnified losses for which we are entitled to
      indemnification equals or exceeds $400,000, at which point, the indemnifying
      party will be liable for the full amount of all such indemnified losses without
      regard to the $400,000 basket. As of the date hereof, the indemnity escrow
      account holds approximately $1,225,000 of cash and 526,810 shares of our common
      stock. We also intend to review various other legal remedies that may be
      available to us.




-29-
 **Back
          to Table of Contents**




The
      Company is also subject to other legal proceedings, claims and litigation
      arising in the ordinary course of business. While the outcome of these matters
      is currently not determinable, management does not expect that the ultimate
      costs to resolve these matters will have a material adverse effect on the
      Company's consolidated financial position, results of operations, or cash
      flows.





**Item
      1A. Risk Factors**





*We
      operate in a rapidly changing environment that involves a number of risks,
      some
      of which are beyond our control. This discussion highlights some of the risks
      that may affect future operating results. The risks described below are not
      the
      only ones facing us. Additional risks and uncertainties not presently known
      to
      us, which we currently deem immaterial or which are similar to those faced
      by
      other companies in our industry or business in general, may also impair our
      business operations. If any of the following risks or uncertainties actually
      occurs, our business, financial condition and operating results would likely
      suffer.*




**We
      have experienced significant losses and may continue to incur such losses in
      the
      future. As a result, the amount of our cash, cash equivalents, and investments
      in marketable securities has materially declined. We recently raised $24 million
      in a private placement of our common stock; however, if we continue to incur
      significant losses and are unable to access sufficient working capital from
      our
      operations or through external financings, we will be unable to adequately
      fund
      future operations and operate as a going concern.**





We
      have
      incurred substantial net losses in each of the last six fiscal years, and in
      the
      six months ended April 30, 2006. As reflected in our financial statements in
      our
      Annual Report on Form 10-K, we have experienced net losses of $55.5 million,
      $36.3 million, and $9.4 million in our fiscal years ended October 31, 2005,
      2004
      and 2003, respectively, and a net loss of $6.3 million in the six months ended
      April 30, 2006. As a result, the amount of our cash, cash equivalents, and
      investments in marketable securities has significantly declined from
      approximately $49.1 million at October 31, 2003 to $1.8 million at April 30,
      2006. The decrease over the past two year period ended October 31, 2005, was
      primarily attributed to net cash payments of $26.3 million used in continuing
      operating activities, $13.2 million related to our acquisition of NOMOS, $9.0
      million used in the discontinued Theseus operations, and $1.6 million used
      for
      capital expenditures, partially offset by $4.6 million in cash received from
      the
      exercise of stock options and our employee stock purchase plan. The decrease
      in
      the six months ended April 30, 2006 was primarily due to $8.1 million of cash
      used in operating activities, partially offset by a $6.3 million drawdown on
      our
      bank line of credit and long-term debt facility.





The
      negative cash flow we have sustained has materially reduced our working capital,
      which in turn, could materially and negatively impact our ability to adequately
      fund future operations and continue to operate as a going concern. Management
      has and continues to take actions to improve our results. These actions include
      reducing cash operating expenses, developing new technologies and products,
      improving existing technologies and products, and expanding into new
      geographical markets. **** The
      availability of necessary working capital, however, is subject to many factors
      beyond our control, including,
      our ability to obtain favorable financing, economic cycles, market acceptance
      of
      our products, competitors’ responses to our products, the intensity of
      competition in our markets, the level of demand for our products
      etc.





The
      amount of working capital that we will need in the future will also depend
      on
      our efforts and many factors, including:





•
            Our
                ability to successfully market and sell our
                products;


•
            Continued
                scientific progress in our discovery and research
                programs;






-30-
 **Back
          to Table of Contents**




•
            Levels
                of sales and marketing that will be required to launch future products
                and
                achieve and maintain a competitive position in the marketplace for
                both
                existing and new products;


•
            Levels
                of inventory and accounts receivable that we
                maintain;


•
            Level
                of capital expenditures;


•
            Acquisition
                or development of other businesses, technologies or
                products;


•
            The
                time and costs involved in obtaining regulatory approvals;


•
            The
                costs involved in preparing, filing, prosecuting, maintaining, defending,
                and enforcing patent claims; and


•
            The
                potential need to develop, acquire or license new technologies and
                products.





If
      we are
      unsuccessful in these efforts or if any or some of these factors negatively
      impact us, we will need to raise additional capital, reduce operations or take
      other steps to achieve positive cash flow. Although we cannot assure you that
      we
      will be successful in these efforts or that any or some of these factors will
      not negatively impact us, we believe that with the proceeds of the equity
      offering completed on June 7, 2006 we will have sufficient cash to sustain
      us through
      at least the next twelve months .





**Success
      of our recently announced plans to develop a breast brachytherapy product will
      be dependent upon a variety of factors.**





We
      recently announced the development of a new brachytherapy product for the
      treatment of breast cancer. We expect that this product may generate
      significant revenues in the future; however, there are a number of factors
      which
      could adversely affect our ability to achieve this goal, including:




·
            Successful
                completion of the development and launch of this product, including
                receiving all necessary regulatory
                approvals;


·
            Our
                ability to protect our intellectual property through patents and
                licenses;


·
            Our
                ability to successfully manufacture production quantities of the
                product;


·
            The
                acceptance of the product by physicians and health professionals;
                and


·
            Our
                ability to hire and train a direct sales force to sell the
                product;





**Future
      financing transactions will have a dilutive effect on our existing shareholders.**





The
      Company recently completed a private placement of shares of its common stock
      that also includes a significant number of warrants. This financing resulted
      in
      significant dilution of the Company’s current shareholders. In the future, the
      Company may issue additional equity, debt or convertible securities to raise
      capital. If the Company does so, the percentage ownership of the Company held
      by
      existing shareholders would be further reduced, and existing shareholders would
      experience significant
      dilution. In addition, new investors in the Company may demand rights,
      preferences or privileges that differ from, or are senior to, those of our
      existing shareholders, such as warrants in addition to the securities purchased
      and other protections against future dilutive transactions. In addition, any
      capital we may be able to raise could result in increased debt on our balance
      sheet, additional interest and financing expense and/or decreased operating
      income.




-31-
 **Back
          to Table of Contents**





**We
      may be required to record additional goodwill impairment in the
      future.**




Under
      SFAS 142 and SFAS 144, goodwill and intangible assets having an indefinite
      life
      are not amortized but are subject to testing at least annually or more often
      if
      an event occurs or circumstances indicate that the carrying values for goodwill
      and/or intangible assets may be impaired, using a fair value based approach.
      Accounting for impairment contains uncertainty because management must use
      judgment in determining appropriate assumptions to be used in the measurement
      of
      fair value. The Company engaged an appraisal firm to perform an analysis of
      the
      goodwill and intangible assets acquired from NOMOS, to determine the fair value
      thereof under the applicable standards as of the Company’s annual test date of
      September 30, 2005. As a result of this testing, in the fourth quarter of 2005,
      the Company recorded impairments of goodwill and intangible assets of NOMOS
      in
      the amount of $39,884,000, and impairments of goodwill and intangible assets
      of
      Radiation Therapy Products (“RTP”) in the amount of $329,000, in each case due
      to negative operating performance indications including declining sales and
      continued operating losses of the respective business segments.




The
      Company will continue to monitor impairment indicators in any of our reporting
      segments. If our future financial performance or other events indicate that
      the
      value of our recorded goodwill or intangible assets is further impaired, we
      may
      record additional impairment charges that could have a material adverse effect
      on our reported results.




**All
      of our product lines are subject to intense competition. Our most significant
      competitors have greater resources than we do. As a result, we cannot be certain
      that our competitors will not develop superior technologies or otherwise be
      able
      to compete against us more effectively. If we fail to maintain our competitive
      position in key product areas, we may lose significant sources of
      revenue.**




We
      expect
      that our intensity-modulated radiation therapy, or IMRT, and image-guided
      radiation therapy, or IGRT, product lines, including CORVUS, PEACOCK and BAT,
      will generate a substantial part of our revenues in fiscal year 2006. We will
      need to continue to develop enhancements to these products and improvements
      on
      our core technologies in order to compete effectively. Rapid change and
      technological innovation characterize the marketplace for medical products,
      and
      our competitors could develop technologies that are superior to our products
      or
      that render such products obsolete. We anticipate that expenditures for research
      and development will continue to be significant. The domestic and foreign
      markets for radiation therapy equipment are highly competitive. Many of our
      competitors and potential competitors have substantial installed bases of
      products and significantly greater financial, research and development,
      marketing and other resources than we do. Competition may increase as emerging
      and established companies enter the field. In addition, the marketplace could
      conclude that the tasks our products were designed to perform are no longer
      elements of a generally accepted treatment regimen. This could result in us
      having to reduce production volumes or discontinue production of one or more
      IMRT/IGRT products.




Our
      single largest competitor in the IMRT/IGRT market is Varian Medical
      Systems, Inc. (“Varian”). Varian is the largest worldwide manufacturer, in
      terms of market share, of linear accelerators. Linear accelerators are the
      machines that generate the radiation energy beams used in both IMRT and
      conventional radiation treatment. Varian also markets its own line of IMRT
      products, including several models
      of
      multileaf collimators and an IMRT inverse planning software package, which
      it
      often includes with its linear accelerators. Varian is also one of the principal
      providers of record and verification systems, which are systems that keep track
      of all critical information in the treatment of radiation therapy patients
      and
      which allow the planning system to communicate with the linear accelerator.
      Varian recently acquired Zmed, Inc., one of our principal competitors for
      BAT. Varian expects the acquisition to enhance its 3-D ultrasound imaging
      capabilities and offer radiation oncology departments a new line of stereotactic
      positioning accessories and planning software, allowing Varian to directly
      compete against BAT.




-32-
 **Back
          to Table of Contents**




We
      also
      compete with Siemens and Elekta, each of which manufactures one or more
      multileaf collimators that compete with MIMiC and, therefore, with our
      integrated system, PEACOCK. There are several other companies that currently
      offer or plan to offer IMRT modules, which typically add IMRT functionality
      to
      conventional radiation treatment planning products.




Finally,
      we compete with all manufacturers of conventional radiation therapy products
      many of which are devoting substantial resources to promoting their
      products.




Our
      brachytherapy business is also subject to intense competition. Our primary
      competitors in the brachytherapy seed business include: Nycomed Amersham PLC
      (through its control of Oncura) and C.R Bard, Inc., both of whom
      manufacture and sell Iodine-125 brachytherapy seeds, as well as distribute
      Palladium-103 seeds manufactured by a third party (in the case of Oncura, we
      currently manufacture a portion of its Palladium-103 seed requirements pursuant
      to a distribution agreement reached in July, 2005); Mentor, which manufactures
      and sells Iodine-125 brachytherapy seeds and currently distributes third party
      manufactured Palladium-103 brachytherapy seeds; and Theragenics Corporation,
      which manufacturers Palladium-103 seeds and sells Palladium-103 and Iodine-125
      brachytherapy seeds directly and its Palladium-103 brachytherapy seeds through
      marketing relationships with third parties. Several additional companies
      currently sell brachytherapy seeds as well. Recent market changes have also
      provided additional competition for brachytherapy-related services, such as
      pre-loading needles with seeds and placing seeds in so-called
“strands.”




Our
      radiation reference source business also is subject to intense competition.
      Competitors in this industry include AEA Technology PLC and Eckert &
Ziegler AG. We believe that these companies have a dominant position in the
      market for radiation reference source products.




Because
      we are a relatively small company, there is a risk that potential customers
      will
      purchase products from larger manufacturers, even if our products are
      technically superior, based on the perception that a larger, more established
      manufacturer may offer greater certainty of continued product improvements,
      support and service, which could cause our revenues to decline. In addition, many
      of
      our competitors are substantially larger and have greater sales, marketing
      and
      financial resources than we do. Developments by any of these or other companies
      or advances by medical researchers at universities, government facilities or
      private laboratories could render our products obsolete. Moreover, companies
      with substantially greater financial resources, as well as more extensive
      experience in research and development, the regulatory approval process,
      manufacturing and marketing, may be in a better position to seize market
      opportunities created by technological advances in our industry.





**We
      are highly dependent on our direct sales organization, which is small compared
      to many of our competitors and which has relatively limited marketing and sales
      experience in our products. We have also experienced a high degree of turnover
      in our sales organization. Any failure to build, manage and maintain our direct
      sales organization could negatively affect our revenues.**




Our
      current domestic direct sales force is small relative to many of our
      competitors. There is intense competition for skilled sales and marketing
      employees, particularly for people who have experience in the radiation oncology
      market. Accordingly, we could find it difficult to hire or retain skilled
      individuals to sell our products. Any failure to build our direct sales force
      could adversely affect our growth and our ability to meet our revenue
      goals.




We
      have
      experienced a higher than anticipated turnover in our domestic direct sales
      force which has resulted in a relative lack of experience in selling our
      products. As a result of our relatively small sales force, the intense
      competition for skilled sales and marketing employees ,
      and the
      high turnover in our sales force, there can be no assurance that our direct
      sales and marketing efforts will be successful. If we are not successful in
      our
      direct sales and marketing, our sales revenue and results of operations are
      likely to be materially adversely affected.




-33-
 **Back
          to Table of Contents**




**We
      depend partially on our relationships with distributors and other industry
      participants to market some of our products, and if these relationships are
      discontinued or if we are unable to develop new relationships, our revenues
      could decline.**




We
      currently rely, and will continue to rely, upon collaborative relationships
      with
      agents and distributors and other industry participants to maintain IMRT/IGRT
      market access to potential customers, particularly in Asia and Europe, and
      our
      business strategy includes entering into more of these relationships in the
      future. Some of the entities with whom we have relationships to help market
      and
      distribute our products also produce or distribute products that directly
      compete with our IMRT/IGRT products.




We
      cannot
      assure you that we will be able to maintain or develop these relationships
      with
      agents and distributors and other industry participants or that these
      relationships will continue to be successful. If any of these relationships
      is
      terminated, not renewed or otherwise unsuccessful, or if we are unable to
      develop additional relationships, our product sales could decline, and our
      ability to grow our IMRT/IGRT business could be adversely affected. This is
      particularly the case with respect to foreign sales of our IMRT/IGRT products,
      where we currently rely, and we will continue to rely, on our distributors'
      expertise regarding foreign regulatory matters and their access to actual and
      potential customers.




In
      addition, our 2005 agreement with Oncura for distribution of our Palladium-103
      brachytherapy seeds may be an important component of that business.




We
      do not
      have a direct sales force for our non-therapeutic radiation source products,
      and
      rely entirely on the efforts of agents and distributors for sales of those
      non-brachytherapy products. We cannot assure you that we will be able to
      maintain our existing relationships with our agents and distributors for the
      sale of our non-therapeutic radiation source products.




**One
      of our primary markets in our IMRT product line is the market for upgrading
      linear accelerators that do not have IMRT capabilities to provide them with
      IMRT
      capabilities. This market will shrink over time, thereby limiting our potential
      revenues from the upgrading of linear accelerators.**




To
      date,
      a majority of our revenues from the sale of our IMRT products has been derived
      from the sale of these products to customers who decide to upgrade linear
      accelerators that do not have IMRT capabilities to enable them to deliver IMRT
      treatments. Most of these linear accelerators are older models. Selling CORVUS
      to customers with newer multileaf collimator-equipped linear accelerators can
      be
      difficult because these linear accelerators may be offered with IMRT planning
      software at little or no additional cost. Accordingly, to make a sale, we often
      must convince these potential customers that CORVUS is sufficiently superior
      to
      the IMRT or conventional radiation treatment planning software products offered
      by the manufacturer to justify the additional costs of purchase. Selling PEACOCK
      and MIMiC to potential customers with newer multileaf collimator-equipped linear
      accelerators is even more difficult because, in addition to the incremental
      costs of purchase, these potential customers may be reluctant to incur the
      additional effort required to retrofit the factory installed multileaf
      collimator with MIMiC. Over time, if more institutions purchase new linear
      accelerators that are IMRT-equipped or upgrade
      their older accelerators with technology from us or our competitors, the market
      for upgrading linear accelerators that do not have IMRT capabilities will shrink
      and may become saturated, which could adversely affect our sales and limit
      our
      potential revenues from our products.




-34-
 **Back
          to Table of Contents**




**If
      we are unable to complete current developments or to develop new enhancements
      and new generations of IMRT/IGRT and/or brachytherapy products, we may be unable
      to retain our existing customers or attract new customers.**




Rapid
      and
      significant technological change, evolving industry standards and new product
      introductions characterize the market for our products. Many of our products
      are
      technologically innovative and require significant planning, design, development
      and testing. These activities require significant capital commitments and
      investment. If we are unable to raise needed capital on favorable terms or
      at
      all, we may be unable to maintain our competitive advantage in the
      marketplace.




New
      product developments in the healthcare industry are inherently risky and
      unpredictable. These risks include:




•
            failure
                to prove feasibility;


•
            time
                required from proof of feasibility to routine production;


•
            timing
                and cost of regulatory approvals and clearances;


•
            competitors'
                response to new product developments;


•
            manufacturing,
                installation, warranty and maintenance cost overruns;


•
            failure
                to obtain customer acceptance and payment;


•
            customer
                demands for retrofits of both old and new products; and


•
            excess
                inventory caused by phase-in of new products and phase-out of old
                products.




The
      high
      cost of technological innovation is coupled with rapid and significant change
      in
      the regulations governing the products that compete in our market, by industry
      standards that could change on short notice, and by the introduction of new
      products and technologies that could render existing products and technologies
      uncompetitive. We cannot be sure that we will be able to successfully develop
      new products or enhancements to our existing products. Without successful new
      product introductions, our revenues will likely suffer. Even if customers accept
      new or enhanced products, the costs associated with making these products
      available to customers, as well as our ability to obtain capital to finance
      such
      costs, could reduce or prevent us from increasing our operating margins. We
      are
      currently awaiting FDA 510(k) clearance for our nomosSTAT product, which
      represents the next generation of our currently marketed PEACOCK product. The
      successful introduction of nomosSTAT is critical to our ability to achieve
      our
      sales targets for fiscal 2006. Any unforeseen delay in 510(k) clearance from
      the
      FDA, or lack of acceptance in the market following such clearance, may result
      in
      a materially adverse impact on our financial results.




In
      addition, although we have received FDA 510(k) clearance for our PEREGRINE
      dose
      calculation software product, and it may now be used clinically to treat
      patients for one linear accelerator beam modifier combination, we are still
      in
      the process of finalizing the development of PEREGRINE in order to allow it
      to
      be used with a broader range of linear accelerators, energy levels with those
      linear accelerators, and treatment planning systems without the need for
      extensive commissioning and testing. An inability to complete these developments
      on a timely basis could adversely affect our relationship with the early
      purchasers of PEREGRINE, and could adversely impact our ability to sell
      PEREGRINE to new customers. Any failure to successfully complete these
      developments could also hurt our reputation and, therefore, adversely impact
      sales of other our products.





**We
      might not be able to make our IMRT products compatible with some existing linear
      accelerators and other radiation therapy products. In addition, any future
      changes in the configuration of the most common linear accelerators could
      require costly and time-consuming modifications to our products that could
      harm
      our business.**




Our
      IMRT
      products are designed to be used in conjunction with most linear accelerators
      currently in use. Our products are not currently compatible with all linear
      accelerators. However, when manufacturers modify the design or functionality
      of
      their machines, we are often required to modify our products to ensure
      compatibility. Future changes cannot be predicted and, in the case of changes
      initiated by linear accelerator manufacturers who are our competitors, could
      be
      made or timed to place us at a competitive disadvantage. Responding to these
      changes can be costly and time-consuming. In addition, we could be required
      to
      obtain additional regulatory clearances for any modifications of our products.
      It is also possible that, despite our best efforts, we might be unable to make
      our products compatible with new or modified versions of linear accelerators
      or
      might only be able to do so at a prohibitive expense.




-35-
 **Back
          to Table of Contents**




Our
      PEREGRINE product is not currently fully compatible with the majority of the
      linear accelerators in the United States and worldwide markets. We cannot assure
      you that we will be successful in making PEREGRINE compatible with additional
      linear accelerators, and any future changes in the design of any linear
      accelerators could require us to redesign the functionality of PEREGRINE. We
      may
      not be successful at any such effort.




**If
      alternative technologies prove to be superior to IMRT/IGRT or brachytherapy,
      physician adoption of our products could substantially decrease.**




Our
      IMRT/IGRT products face competition from companies that sell conventional
      radiation therapy products as well as from companies that are developing,
      marketing and manufacturing alternative therapies to radiation for the treatment
      of solid tumor cancers. It is possible that advances in the pharmaceutical,
      bio-medical or gene-therapy fields could render some or all radiation therapies,
      whether conventional or based on IMRT/IGRT and brachytherapy, obsolete. Even
      incremental advances in competing technologies could result in the rejection
      of
      our products as a part of a generally accepted diagnostic or treatment regimen.
      If alternative therapies are proven or perceived to offer treatment options
      that
      are superior or more cost effective than the treatments our products provide,
      physician adoption of our products could be negatively affected and our revenues
      from our products could decline.




**There
      is currently a lack of long-term data regarding the safety and effectiveness
      of
      IMRT products and negative data or the continued lack of adequate supporting
      data could adversely affect market acceptance of our IMRT products.**




Although
      we estimate that our IMRT products have been used to treat thousands of patients
      worldwide, this is still a statistically small number, and these treatments
      have
      primarily involved tumors of the prostate, head, neck and spinal cord. Much
      of
      the data produced in current studies using IMRT and our products have involved
      small patient sample sizes, and any positive results of these studies may not
      be
      representative of the results that will be achieved in studies involving larger
      patient sample sizes. If we are unable to obtain additional and more
      comprehensive clinical studies, or if long-term clinical studies fail to confirm
      the effectiveness of IMRT or our products, our sales could fail to increase
      or
      could decrease.




Some
      theoretical and non-clinical studies, meaning studies that are not based on
      significant empirical evidence, have suggested that the use of IMRT and
      potentially our products may cause serious negative side effects, such as a
      risk
      of induced cancer, as a result of the increased radiation delivered to the
      patient. At present, not enough time has passed to determine conclusively the
      long-term side effects. If future clinical studies confirm that these negative
      side effects occur as a result of IMRT treatments, our sales could fail to
      grow
      or could decline. In addition, if it is shown that our products cause harmful
      side effects, the U.S. Food and Drug Administration, or FDA, could require
      us to
      change our product labeling to describe these potential side effects or could
      even rescind the clearances for our products and potentially require a recall
      of
      our products.




IMRT,
      whether using our products or those of our competitors, requires a substantial
      departure from customary quality assurance practices. The complexity and dynamic
      nature of IMRT deliveries make
      new
      demands on patient plan and dose verification. These difficulties and departures
      from customary practices may impede market acceptance of IMRT in general and
      our
      products in particular, which could adversely affect our ability to increase
      sales of our products and achieve our desired growth rate.




-36-
 **Back
          to Table of Contents**




**IMRT
      treatments expose patients to increased radiation leakage, which could
      potentially cause long-term deleterious side effects, including induced cancer.**




In
      both
      IMRT and conventional radiation therapy, there is radiation leakage, which
      means
      radiation that escapes from the linear accelerator and is absorbed by the
      patient outside the area of the patient's body being treated. Linear
      accelerators are the machines that generate the radiation energy beams used
      in
      both IMRT and conventional radiation treatment. Leakage occurs at all times
      when
      the linear accelerator is producing radiation. In IMRT treatments, the linear
      accelerator is required to produce radiation for a longer period of time overall
      as compared to conventional radiation treatments. Also, in IMRT treatments
      there
      is additional leakage that is transmitted through or between the leaves of
      the
      multileaf collimator itself. As a result, there is an increase in the overall
      radiation leakage to which the patient is exposed due to the longer periods
      of
      radiation delivery.




The
      increased radiation leakage associated with IMRT treatments could require
      additional room shielding to protect clinic personnel. In addition, concerns
      have been raised by some researchers that the increase in overall radiation
      leakage to which IMRT patients are exposed may have deleterious long-term
      effects, including the potential for inducing cancer.




These
      same studies suggest that an increase in the long-term risk of induced cancers
      from IMRT may be possible. The risk, or perceived risk, of induced cancers
      could
      slow or prevent expanded use of IMRT to treat additional types of cancers and
      could even result in decreased usage of IMRT to treat cancers currently treated
      with IMRT if the increased risk is shown or believed to be significant, which
      could cause our revenues from our products to decline and our business to
      suffer.




**Our
      IMRT/IGRT products are used in connection with the delivery of intense
      radiation. Defects in, or misuse of, our products, or any detrimental side
      effects that result from the use of our products, could result in serious injury
      or death and could require costly recalls or subject us to costly and
      time-consuming product liability claims. This could harm future sales and
      require us to pay substantial damages.**




Our
      IMRT/IGRT products are used in connection with the delivery of high-powered
      external beam radiation to cancer patients. One or more of our IMRT/IGRT
      products could malfunction or be misused and cause serious injury or death
      to a
      patient. In addition, our IMRT/IGRT products might otherwise be determined
      to
      cause serious injury or other detrimental side effects. There is an inherent
      risk in our industry that we could be sued if one of our products results in,
      or
      is alleged to result in, a personal injury. Although we believe that we
      currently have adequate insurance to address anticipated potential liabilities
      associated with product liability, any unforeseen product liability, exposure
      in
      excess of, or outside the scope of, such insurance coverage could adversely
      affect our operating results. Any such claim brought against us, with or without
      merit, could result in significant damage to our business.




The
      FDA's
      medical device reporting regulations require us to report any incident in which
      our products may have caused or contributed to a death or serious injury, or
      in
      which our products malfunctioned in a way that would be likely to cause or
      contribute to a death or serious injury if the malfunction recurred. Any
      required filing could result in an investigation of our products and possibly
      subsequent regulatory action against us if it is found that one of our products
      caused the death or serious injury of a patient.




Because
      of the nature of our IMRT/IGRT products and their use, the tolerance for error
      in the design, manufacture or use of our IMRT/IGRT products may be small or
      nonexistent. If a product designed
      or manufactured by us is defective, whether due to design or manufacturing
      defects, or improper assembly, use or servicing of the product or other reasons,
      the product may need to be recalled, possibly at our expense. Furthermore,
      the
      adverse effect of a product recall might not be limited to the cost of the
      recall. For example, a product recall could cause applicable regulatory
      authorities to investigate us as well as cause our customers to review and
      potentially terminate their relationships with us. Recalls, especially if
      accompanied by unfavorable publicity or termination of customer contracts,
      could
      cause us to suffer substantial costs, lost revenues and a loss of reputation,
      each of which could harm our business. Products as complex as our planning
      and
      dose calculation software systems may also contain undetected software errors
      or
      defects when they are first introduced or as new versions are released. Our
      products may not be free from errors or defects even after they have been
      tested, which could result in the rejection of our products by our customers
      and
      damage to our reputation, as well as lost revenue, diverted development
      resources and increased support costs. We may also be subject to claims for
      damages related to any errors in our products.




-37-
 **Back
          to Table of Contents**




We
      currently maintain product liability insurance, which has deductible amounts
      and
      per claim and aggregate limits. However, we cannot assure you that this
      insurance will continue to be available on terms acceptable to us or in
      sufficient amounts if at all, or that it will provide adequate coverage in
      the
      event that any product liability is actually incurred.




**Currently,
      our products are predominantly used in the treatment of tumors of the prostate,
      head, neck and spinal cord. If we do not obtain wider acceptance of our products
      to treat other types of cancer, our sales could fail to increase and we could
      fail to achieve our desired growth rate.**




Currently,
      our IMRT/IGRT products are predominantly used in the treatment of tumors of
      the
      prostate, head, neck and spinal cord, while our brachytherapy products are
      used
      almost exclusively for the treatment of prostate cancer. Further research,
      clinical data and years of experience will likely be required before there
      can
      be broad acceptance for the use of both our IMRT/IGRT as well as our
      brachytherapy products for additional types of cancer. In particular, some
      recognized members of the radiation oncology community have expressed skepticism
      as to the relative benefits of IMRT treatments other than for limited types
      of
      cancer such as prostate cancer, where mortality is closely linked to recurrence
      of the local tumor. They point out that in many types of cancer, such as breast
      cancer, mortality is usually a result of metastasis, meaning the expansion
      of
      the cancer to other parts of the patient's body, and that eliminating or
      controlling the growth of the local tumor, which is the goal of IMRT treatments,
      does little to prevent this from occurring. If our products do not become more
      widely accepted in treating other types of cancer, our sales could fail to
      increase or could decrease.




**We
      rely on several sole source suppliers and a limited number of other suppliers
      to
      provide raw materials and significant components used in our products. A
      material interruption in supply could prevent or limit our ability to accept
      and
      fill orders for our products.**




Although
      we perform final product assembly of our IMRT/IGRT products, we purchase all
      major components for those products from third-party suppliers. We currently
      rely on a single source of supply for several key materials and components,
      the
      most important of which are the tungsten leaves used in our MIMiC multi-leaf
      collimator and all major components used in our BAT targeting system. We also
      obtain various other components for our IMRT/IGRT products from a limited number
      of sources. We cannot produce IMRT/IGRT products without these components.
      In
      the event of any extended or recurring interruption in supply, or if any of
      the
      significant components to our IMRT/IGRT products become obsolete or are no
      longer manufactured, we could be required to redesign our products or seek
      alternative supply sources, which could significantly impair our ability to
      sell
      these products. In some cases, we expect that it would take several months,
      or
      longer, for a new supplier to begin providing components to specification.
      In
      addition, we could be required to make a new or supplemental filing with the
      FDA
      and other applicable regulatory authorities and might have to obtain clearance
      or other regulatory approvals prior to marketing a product containing new
      components. We may be unable to obtain
      the necessary regulatory clearances or approvals on a timely basis, if at all,
      which could cause our revenues to decline and our business to suffer.




We
      also
      depend upon a limited number of outside unaffiliated suppliers for our
      radioisotopes. Our principal suppliers are Nordion International, Inc. and
      a company in Russia. We also utilize other commercial isotope manufacturers
      located in the United States and overseas. To date, we have been able to obtain
      the required radioisotopes for our products without any significant delays
      or
      interruptions. Currently, we rely exclusively upon Nordion International for
      our
      supply of the Palladium-103 isotope; if Nordion International ceases to supply
      isotopes in sufficient quantity to meet our needs, there may not be adequate
      alternative sources of supply. If we lose any of these suppliers (including
      any
      single-source supplier), we would be required to find and enter into supply
      arrangements with one or more replacement suppliers. Obtaining alternative
      sources of supply could involve significant delays and other costs and these
      supply sources may not be available to us on reasonable terms or at all. Any
      disruption of supplies could delay delivery of our products that use
      radioisotopes, which could adversely affect our business and financial results
      and could result in lost or deferred sales.




-38-
 **Back
          to Table of Contents**




**If
      we are unable to attract and retain qualified employees, we may be unable to
      meet our growth and revenue needs.**




Our
      success is materially dependent on a limited number of key employees, and,
      in
      particular, the continued services of L. Michael Cutrer, our president and
      chief
      executive officer, and James W. Klingler, our chief financial officer. We carry
      key employee insurance for Mr. Cutrer in the amount of $2.5 million.
      Our future business and financial results could be adversely affected if the
      services of Messrs. Cutrer or Klingler or other key employees cease to be
      available. To our knowledge, none of our key employees have any plans to retire
      or leave in the near future.




Our
      future success and ability to grow our business will depend in part on the
      continued service of our skilled personnel and our ability to identify, hire
      and
      retain additional qualified personnel. Although some employees are bound by
      a
      limited non-competition agreement that they sign upon employment, few of our
      employees are bound by employment contracts, and it is difficult to find
      qualified personnel, particularly medical physicists and customer service
      personnel, who are willing to travel extensively. We compete for qualified
      personnel with medical equipment manufacturers, universities and research
      institutions. Because the competition for these personnel is intense, costs
      related to compensation may increase significantly.




Even
      when
      we are able to hire a qualified medical physicist, engineer or other technical
      person, there is a significant training period of up to several months before
      that person is fully capable of performing the functions we need. This could
      limit our ability to expand our business.





**The
      medical device industry is characterized by competing intellectual property,
      and
      we could be sued for violating the intellectual property rights of others.**




The
      medical device industry is characterized by a substantial amount of litigation
      over patent and other intellectual property rights. Our competitors, like
      companies in many high technology businesses, continually review other
      companies' products for possible conflicts with their own intellectual property
      rights. Determining whether a product infringes a patent involves complex legal
      and factual issues, and the outcome of patent litigation actions is often
      uncertain. Our competitors could assert that our products and the methods we
      employ in the use of our products are covered by United States or foreign patent
      rights held by them. In addition, because patent applications can take many
      years to issue, there could be applications now pending of which we are unaware,
      which could later result in issued patents that our products infringe. There
      could also be existing patents that one or more of our products could
      inadvertently be infringing of which we are unaware.




While
      we
      do not believe that any of our products, services or technologies infringe
      any
      valid intellectual property rights of third parties, we may be unaware of
      third-party intellectual property rights that relate to our products, services
      or technologies. As the number of competitors in the radiation oncology market
      grows, and as the number of patents issued in this area grows, the possibility
      of a patent infringement claim against us going forward increases. We could
      incur substantial costs and diversion of management resources if we have to
      assert our patent rights against others. An unfavorable outcome to any
      litigation could harm us. In addition, we may not be able to detect infringement
      or may lose competitive position in the market before we do so.




-39-
 **Back
          to Table of Contents**




To
      address patent infringement or other intellectual property claims, we may have
      to enter into license agreements and technology cross-licenses or agree to
      pay
      royalties at a substantial cost to us. We may be unable to obtain necessary
      licenses. A valid claim against us and our failure to obtain a license for
      the
      technology at issue could prevent us from selling our products and materially
      adversely affect our business, financial results and future prospects.




**If
      we fail to protect our intellectual property rights or if our intellectual
      property rights do not adequately cover the technologies we employ, or if such
      rights are declared to be invalid, other companies may take advantage of our
      technology ideas and more effectively compete directly against us, or we might
      be forced to discontinue selling certain products.**




Our
      success depends in part on our ability to obtain and enforce patent protections
      for our products and operate without infringing on the proprietary rights of
      third parties. We rely on U.S. and foreign patents to protect our intellectual
      property. We also rely significantly on trade secrets and know-how that we
      seek
      to protect. We attempt to protect our intellectual property rights by filing
      patent applications for new features and products we develop. We enter into
      confidentiality or license agreements with our employees, consultants,
      independent contractors and corporate partners, and we seek to control access
      to
      our intellectual property and the distribution of our products, documentation
      and other proprietary information. We plan to continue these methods to protect
      our intellectual property and our products. These measures may afford only
      limited protection. In addition, the laws of some foreign countries may not
      protect our intellectual property rights to the same extent as do the laws
      of
      the United States.




If
      a
      competitor infringes upon our patent or other intellectual property rights,
      enforcing those rights could be difficult, expensive and time-consuming, making
      the outcome uncertain. Competitors could also bring actions or counterclaims
      attempting to invalidate our patents. Even if we are successful, litigation
      to
      enforce our intellectual property rights or to defend our patents against
      challenge could be costly and could divert our management's
      attention.




In
      1998
      (prior to our acquisition of NOMOS Corporation), NOMOS became involved in a
      lawsuit, which NOMOS initiated, involving a NOMOS patent relating to the
      ultrasound localization techniques that is used in BAT. In January 2003,
      the district court entered judgment against NOMOS on its infringement claims.
      NOMOS appealed this judgment to the United States Court of Appeals for the
      Federal Circuit. In February 2004, the circuit court upheld the district court's
      judgment and we filed a petition for rehearing, which was denied on
      March 11, 2004. We cannot predict what the adverse effect the result of
      this litigation will have on our future sales of related products.




Even
      if
      we are able to effectively enforce our existing proprietary rights to the
      fullest extent permitted by law, this would not protect us from competition.
      We
      do not have any patents on IMRT delivery or planning generally, and we have
      competitors that currently market and sell IMRT planning and delivery products
      including inverse planning systems similar to our CORVUS product. In addition,
      our competitors could design around our patents or develop products that provide
      comparable or superior outcomes without infringing on our patents or other
      proprietary rights. The confidentiality agreements with our employees,
      consultants and other third parties may not be enforceable or may not provide meaningful
      protection for our trade secrets or other proprietary information in the event
      of unauthorized use or disclosure.




In
      2006,
      we licensed intellectual property which is currently the subject of litigation
      brought by WorldWide Medical Technologies in U.S. District Court against both
      the Company as well as their former employee, Richard Terwilliger, who is
      currently our Vice-President of New Product Development. This intellectual
      property relates to the Company’s brachytherapy business, specifically, certain
      needle-loading and stranding technologies. While the Company does not believe
      that it has any liability in this matter, and is vigorously defending itself
      in
      the litigation, we cannot predict what effect an adverse result from this
      litigation would have on our future sales of the products at issue.




-40-
 **Back
          to Table of Contents**




**We
      use radioactive materials which are subject to stringent regulation and which
      may subject us to liability if accidents occur** .





We
      manufacture and process radioactive materials which are subject to stringent
      regulation. We operate under licenses issued by the California Department of
      Health which are renewable every eight years. We received a renewal of our
      license for our North Hollywood facility in 1998 and we were issued a license
      for our Chatsworth facility in March 1999. California is one of the
      "Agreement States," which are so named because the Nuclear Regulatory
      Commission, or NRC, has granted such states regulatory authority over
      radioactive materials, provided such states have regulatory standards meeting
      or
      exceeding the standards imposed by the NRC. Most users of our products must
      obtain licenses issued by the state in which they reside (if they are Agreement
      States) or the NRC. Use licenses are also required by some of the foreign
      jurisdictions in which we may seek to market our products.





Although
      we believe that our safety procedures for handling and disposing of these
      radioactive materials comply with the standards prescribed by state and federal
      regulations, the risk of accidental contamination or injury from these materials
      cannot be completely eliminated. In the event of such an accident, we could
      be
      held liable for any damages that result. We believe we carry reasonably adequate
      insurance to cover us in the event of any damages resulting from the use of
      hazardous materials.




**Healthcare
      reforms, changes in health-care policies and unfavorable changes to third-party
      reimbursements for use of our products, could cause declines in the revenues
      of
      our products.**




Hospitals
      and freestanding clinics may be less likely to purchase our products if they
      cannot be assured of receiving favorable reimbursement for treatments using
      our
      products from third-party payors, such as Medicare, Medicaid and private health
      insurance plans. Generally speaking, Medicare pays hospitals, freestanding
      clinics and physicians a fixed amount for services using our products,
      regardless of the costs incurred by those providers in furnishing the services.
      Such providers may perceive the set reimbursement amounts as inadequate to
      compensate for the costs incurred and thus may be reluctant to furnish the
      services for which our products are designed. Moreover, third-party payors
      are
      increasingly challenging the pricing of medical procedures or limiting or
      prohibiting reimbursement for some services or devices, and we cannot be sure
      that they will reimburse our customers at levels sufficient to enable us to
      achieve or maintain sales and price levels for our products. There is no uniform
      policy on reimbursement among third-party payors, and we can provide no
      assurance that procedures using our products will qualify for reimbursement
      from
      third-party payors or that reimbursement rates will not be reduced or
      eliminated. For example, we have previously been informed that some private
      third-party payors regard IMRT as investigational or experimental and do not
      provide reimbursement for these services at this time. A reduction in or
      elimination of third-party payor reimbursement for treatments using our products
      would likely have a material adverse effect on our revenues.




Furthermore,
      any federal and state efforts to reform government and private healthcare
      insurance programs could significantly affect the purchase of healthcare
      services and products in general and demand for our products in particular.
      We
      are unable to predict whether potential reforms will be enacted, whether other
      healthcare legislation or regulation affecting the business may be proposed
      or enacted
      in the future or what effect any such legislation or regulation would have
      on
      our business, financial condition or results of operations.




The
      federal Medicare program currently reimburses hospitals and freestanding clinics
      for both IMRT/IGRT and brachytherapy treatments. Medicare reimbursement amounts
      typically are reviewed and adjusted at least annually. Medicare reimbursement
      policies are reviewed and revised on an ad hoc basis. Adjustments could be
      made
      to these reimbursement policies or amounts, which could result in reduced or
      no
      reimbursement for IMRT/IGRT and brachytherapy services. Changes in Medicare
      reimbursement policies or amounts affecting hospitals and freestanding clinics
      could negatively affect market demand for our products.




-41-
 **Back
          to Table of Contents**




With
      respect to brachytherapy in particular, Medicare reimbursement amounts for
      seeding are currently significantly less than for radical prostatectomy, or
      RP.
      Although seeding generally requires less physician time than RP, lower
      reimbursement amounts, when combined with physician familiarity with RP, may
      create disincentives for urologists to perform seeding.




Private
      third-party payors often adopt Medicare reimbursement policies and payment
      amounts. As such, Medicare reimbursement policy and payment amount changes
      concerning our products also could be extended to private third-party payor
      reimbursement policies and amounts and could affect demand for our products
      in
      those markets as well.




Acceptance
      of our products in foreign markets could be affected by the availability of
      adequate reimbursement or funding, as the case may be, within prevailing
      healthcare payment systems. Reimbursement, funding and healthcare payment
      systems vary significantly by country and include both government-sponsored
      healthcare and private insurance. We can provide no assurance that third-party
      reimbursement will be made available with respect to treatments using our
      products under any foreign reimbursement system.




Problems
      with any of these reimbursement systems that adversely affect demand for our
      products could cause our revenues from our products to decline and our business
      to suffer.




Also,
      we,
      our distributors and healthcare providers performing radiation therapy
      procedures are subject to state and federal fraud and abuse laws prohibiting
      kickbacks and, in the case of physicians, patient self-referrals. We may be
      subjected to civil and criminal penalties if we or our agents violate any of
      these prohibitions.





**We
      are subject to extensive government regulation applicable to the manufacture
      and
      distribution of our products. Complying with the Food And Drug Administration
      and other domestic and foreign regulatory bodies is an expensive and
      time-consuming process, whose outcome can be difficult to predict. If we fail
      or
      are delayed in obtaining regulatory approvals or fail to comply with applicable
      regulations, we may be unable to market and distribute our products or may
      be
      subject to civil or criminal penalties.**





We
      and
      some of our suppliers and distributors are subject to extensive and rigorous
      government regulation of the manufacture and distribution of our products,
      both
      in the United States and in foreign countries. Compliance with these laws and
      regulations is expensive and time-consuming, and changes to or failure to comply
      with these laws and regulations, or adoption of new laws and regulations, could
      adversely affect our business.





In
      the
      United States, as a manufacturer and seller of medical devices and devices
      utilizing radioactive by-product material, we and some of our suppliers and
      distributors are subject to extensive regulation by federal governmental
      authorities, such as the United States Food and Drug Administration, or FDA,
      and
      state and local regulatory agencies, such as the State of California, State
      of
      Pennsylvania and the State of Washington **** to
      ensure
      such devices are safe and effective. Such regulations, which include the U.S. Food,
      Drug and Cosmetic Act, or the FDC Act, and regulations promulgated by the FDA,
      govern the design, development, testing, manufacturing, packaging, labeling,
      distribution, import/export, possession, marketing, disposal, clinical
      investigations involving humans, sale and marketing of medical devices,
      post-market surveillance, repairs, replacements, recalls and other matters
      relating to medical devices, radiation producing devices and devices utilizing
      radioactive by-product material. State regulations are extensive and vary from
      state to state. Our brachytherapy seeds and IMRT/IGRT products constitute
      medical devices subject to these regulations. Future products in any of our
      business segments may constitute medical devices and be subject to regulation
      as
      such. These laws require that manufacturers adhere to certain standards designed
      to ensure that the medical devices are safe and effective. Under the FDC Act,
      each medical device manufacturer must comply with requirements applicable to
      manufacturing practices.




-42-
 **Back
          to Table of Contents**




In
      the
      United States, medical devices are classified into three different categories,
      over which the FDA applies increasing levels of regulation: Class I,
      Class II, and Class III. The FDA has classified all of our IMRT/IGRT
      products to date as Class II devices. Our brachytherapy products have been
      classified as Class I devices. Before a new device can be introduced into the
      United States market, the manufacturer must obtain FDA clearance or approval
      through either a 510(k) premarket notification or a premarket approval, unless
      the product is otherwise exempt from the requirements. Class I devices are
      statutorily exempt from the 510(k) process, unless the device is intended for
      a
      use which is of substantial importance in preventing impairment of human health
      or it presents a potential unreasonable risk of illness or injury.




A
      510(k)
      premarket notification clearance will typically be granted for a device that
      is
      substantially equivalent to a legally marketed Class I or Class II
      medical device or a Class III medical device for which the FDA has not yet
      required submission of a premarket approval. A 510(k) premarket notification
      must contain information supporting the claim of substantial equivalence, which
      may include laboratory results or the results of clinical studies. Following
      submission of a 510(k) premarket notification, a company may not market the
      device for clinical use until the FDA finds the product is substantially
      equivalent for a specific or general intended use. FDA clearance generally
      takes
      from four to twelve months, but it may take longer, and there is no assurance
      that the FDA will ultimately grant a clearance. The FDA may determine that
      a
      device is not substantially equivalent and require submission and approval
      of a
      premarket approval or require further information before it is able to make
      a
      determination regarding substantial equivalence.




Most
      of
      the products that we are currently marketing have received clearances from
      the
      FDA through the 510(k) premarket notification process. For any devices already
      cleared through the 510(k) process, modifications or enhancements that could
      significantly affect safety or effectiveness, or constitute a major change
      in
      intended use require a new 510(k) submission and a separate FDA determination
      of
      substantial equivalence. We have made minor modifications to our products and,
      using the guidelines established by the FDA, have determined that these
      modifications do not require us to file new 510(k) submissions. If the FDA
      disagrees with our determinations, we may not be able to sell one or more of
      our
      products until the FDA has cleared new 510(k) submissions for these
      modifications, and there is no assurance that the FDA will ultimately grant
      a
      clearance. In addition, the FDA may determine that future products require
      the
      more costly, lengthy and uncertain premarket approval process under
      Section 515 of the FDC. The approval process under Section 515
      generally takes from one to three years, but in many cases can take even longer,
      and there can be no assurance that any approval will be granted on a timely
      basis, if at all. Under the premarket approval process, an applicant must
      generally conduct at least one clinical investigation and submit extensive
      supporting data and clinical information establishing the safety and
      effectiveness of the device, as well as extensive manufacturing information.
      Clinical investigations themselves are typically lengthy and expensive, closely
      regulated and frequently require prior FDA clearance. Even if clinical
      investigations are conducted, there is no assurance that they will support
      the
      claims for the product. If the FDA requires us to submit a new premarket
      notification under Section 510(k) for modifications to our existing
      products, or if the FDA requires us to go through the lengthier, more rigorous
      Section 515 premarket approval process, our product introductions or
      modifications could be delayed or cancelled, which could cause our revenues
      to
      be below expectations.




In
      addition to FDA-required market clearances and approvals, our manufacturing
      operations are required to comply with the FDA's Quality System Regulation,
      or
      QSR, which addresses the quality program requirements, such as a company's
      management responsibility for the company's quality systems, and good
      manufacturing practices, product design, controls, methods, facilities and
      quality assurance controls used in manufacturing, assembly, packing, storing
      and
      installing medical devices. Compliance with the QSR is necessary to receive
      FDA
      clearance or approval to market new products and is necessary for us to be
      able
      to continue to market cleared or approved product offerings. There
      can
      be no assurance that we will not incur significant costs to comply with these
      regulations in the future or that the regulations will not have a material
      adverse effect on our business, financial condition and results of operations.
      Our compliance and the compliance by some of our suppliers with applicable
      regulatory requirements is and will continue to be monitored through periodic
      inspections by the FDA. The
      FDA
      makes announced and unannounced inspections to determine compliance with the
      QSR's and may issue us 483 reports listing instances where we have failed to
      comply with applicable regulations and/or procedures or Warning Letters which,
      if not adequately responded to, could lead to enforcement actions against us,
      including fines, the total shutdown of our production facilities and criminal
      prosecution.




-43-
 **Back
          to Table of Contents**




If
      we or
      any of our suppliers fail to comply with FDA requirements, the FDA can institute
      a wide variety of enforcement actions, ranging from a public warning letter
      to
      more severe sanctions such as:




•
            fines,
                injunctions and civil penalties;


•
            the
                recall or seizure of our products;


•
            the
                imposition of operating restrictions, partial suspension or total
                shutdown
                of production;


•
            the
                refusal of our requests for 510(k) clearance or premarket approval
                of new
                products;


•
            the
                withdrawal of 510(k) clearance or premarket approvals already granted;
                and


•
            criminal
                prosecution.




Similar
      consequences could arise from our failure, or the failure by any of our
      suppliers, to comply with applicable foreign laws and regulations. Foreign
      regulatory requirements vary by country. In general, our products are regulated
      outside the United States as medical devices by foreign governmental agencies
      similar to the FDA. However, the time and cost required to obtain regulatory
      approvals from foreign countries could be longer than that required for FDA
      clearance and the requirements for licensing a product in another country may
      differ significantly from the FDA requirements. We rely, in part, on our foreign
      distributors to assist us in complying with foreign regulatory requirements.
      We
      may not be able to obtain these approvals without incurring significant expenses
      or at all, and the failure to obtain these approvals would prevent us from
      selling our products in the applicable countries. This could limit our sales
      and
      growth.




**Doctors
      and hospitals may not adopt our products and technologies at levels sufficient
      to sustain our business or to achieve our desired growth rate.**




Intensity
      modulated radiation therapy and image-guided radiation therapy are both
      relatively new technologies and, to date, we have attained only limited
      penetration of the total potential worldwide market. Our future growth and
      success depends upon creating broad awareness and acceptance of IMRT/IGRT
      generally and our products in particular by doctors, hospitals and freestanding
      clinics, as well as patients. This will require substantial marketing and
      educational efforts, which will be costly and may not be successful. The target
      customers for our IMRT/IGRT products may not adopt these technologies or may
      adopt them at a rate that is slower than desired. In addition, as described
      above, potential customers who decide to utilize IMRT/IGRT may choose to
      purchase competitors' products. Important factors that will affect our ability
      to attain broad market acceptance of our IMRT/IGRT products include:




•
            doctor
                and patient awareness and acceptance of IMRT/IGRT and our products;


•
            the
                real or perceived effectiveness and safety of IMRT/IGRT and our products;


•
            the
                relationship between the cost of our products and the real or perceived
                medical benefits ofIMRT/IGRT
                and our products;


•
            the
                relationship between the cost of our products and the financial benefits
                to our customers of using our products, which will be greatly affected
                by
                the coverage of, and reimbursement for, IMRT/IGRT treatment and ultrasound
                guidance by governmental and private third-party payors; and


•
            market
                perception of our ability to continue to grow our business and develop
                enhanced IMRT/IGRT products.




Failure
      of our products to gain broad market acceptance could cause our revenues to
      decline and our business to suffer.




-44-
 **Back
          to Table of Contents**




**Our
      future growth depends, in part, on our ability to penetrate foreign markets,
      particularly in Asia and Europe. However, we may encounter difficulties in
      gaining acceptance of our products in foreign markets, where we have limited
      experience marketing, servicing and distributing our products, and where we
      will
      be subject to additional regulatory burdens and other
      risks.**




Our
      future profitability will depend in part on our ability to establish, grow
      and
      ultimately maintain our product sales in foreign markets, particularly in Asia
      and Europe. However, we have limited experience in marketing, servicing and
      distributing our products in other countries. In 2005, less than 5% of our
      product revenues and less than 5% of our total revenues were derived from sales
      to customers outside the United States and Canada. Our foreign operations
      subject us to additional risks and uncertainties, including:




•
            our
                customers' ability to obtain reimbursement for procedures using our
                products in foreign markets;


•
            the
                burden of complying with complex and changing foreign regulatory
                requirements;


•
            language
                barriers and other difficulties in providing long-range customer
                support
                and service;


•
            longer
                accounts receivable collection times;


•
            significant
                currency fluctuations, which could cause our distributors to reduce
                the
                number of products they purchase from us because the cost of our
                products
                to them could fluctuate relative to the price they can charge their
                customers;


•
            reduced
                protection of intellectual property rights in some foreign countries;
                and


•
            the
                interpretation of contractual provisions governed by foreign laws
                in the
                event of a contract dispute.




Our
      foreign sales of our products could also be adversely affected by export license
      requirements, the imposition of governmental controls, political and economic
      instability, trade restrictions, changes in tariffs and difficulties in staffing
      and managing foreign operations. In addition, we are subject to the Foreign
      Corrupt Practices Act, any violation of which could create a substantial
      liability for us and also cause a loss of reputation in the market.




**As
      part of our business strategy, we intend to pursue transactions that may cause
      us to experience significant charges to earnings that may adversely affect
      our
      stock price and financial condition** .





We
      regularly review potential transactions related to technologies, product
      candidates or product rights and businesses complementary to our business.
      Such
      transactions could include mergers, acquisitions, strategic alliances, licensing
      agreements or co-promotion agreements. Our acquisition of Theseus Imaging
      Corporation in October 2000 and the acquisition of NOMOS, in May 2004, are
      examples of such transactions. In the future, if we have sufficient available
      capital, we may choose to enter into such transactions. We may not be able
      to
      successfully integrate newly acquired organizations, products or technologies
      into our business and the process could be expensive and time consuming and
      may
      strain our resources. Depending upon the nature of any transaction, we may
      experience a charge to earnings which could be material.





**Operating
      results for a particular period may fluctuate and are difficult to
      predict.**


The
      results of operations for any fiscal quarter or fiscal year are not necessarily
      indicative of results to be expected in future periods. Our operating results
      have in the past been, and will continue to be, subject to quarterly and annual
      fluctuations as a result of a number of factors. As a consequence, operating
      results for a particular future period are difficult to predict. Such factors
      include the following:





·
            Our
                net sales may grow at a slower rate than experienced in previous
                periods
                and, in particular periods, may
                decline;


·
            Our
                brachytherapy product lines may experience some variability in revenue
                due
                to seasonality. This is primarily due to three major holidays occurring
                in
                our first fiscal quarter and the apparent reduction in the number
                of
                procedures performed during summer months, which could affect our
                third
                fiscal quarter results;






-45-
 **Back
          to Table of Contents**




·
            Estimates
                with respect to the useful life and ultimate recoverability of our
                carrying basis of assets, including goodwill and purchased intangible
                assets, could change as a result of such assessments and
                decisions;


·
            As
                a result of our growth in past periods, our fixed costs have increased.
                With increased levels of spending and the impact of long-term commitments,
                we may not be able to quickly reduce these fixed expenses in response
                to
                short-term business changes;


·
            Acquisitions
                that result in in-process research and development expenses may be
                charged
                fully in an individual quarter;


·
            Sales
                of our IMRT/IGRT products are typically heavier in the final month
                of a
                fiscal quarter, leading to a disproportionately high use of cash
                in the
                first two months of a quarter;


·
            Changes
                or anticipated change in third-party reimbursement amounts or policies
                applicable to treatments using our
                products;


·
            Timing
                of the announcement, introduction and delivery of new products or
                product
                enhancements by us and by our competitors;


·
            The
                possibility that unexpected levels of cancellations of orders or
                backlog
                may affect certain assumptions upon which we base our forecasts and
                predictions of future performance;


·
            Changes
                in the general economic conditions in the regions in which we do
                business;


·
            Unfavorable
                outcome of any litigation; and


·
            Accounting
                adjustments such as those relating to reserves for product recalls
                and
                changes in interpretation of accounting
                pronouncements.





**Being
      a public company significantly increases our administrative
      costs.**





The
      Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the
      SEC
      and listing requirements subsequently adopted by NASDAQ in response to
      Sarbanes-Oxley, have required changes in corporate governance practices,
      internal control policies and audit committee practices of public companies.
      These rules, regulations, and requirements have significantly increased our
      legal, financial, compliance and administrative costs, and have made certain
      other activities more time consuming and costly, as well as requiring
      substantial time and attention of our senior management. The Company expects
      its
      continued compliance with these and future rules and regulations to continue
      to
      require significant resources. These new rules and regulations also may make
      it
      more difficult and more expensive for us to obtain director and officer
      liability insurance in the future, and could make it more difficult for us
      to
      attract and retain qualified members for our Board of Directors, particularly
      to
      serve on our audit committee.





**Our
      publicly-filed SEC reports are reviewed by the SEC from time to time and any
      significant changes required as a result of any such review may result in
      material liability to us and have a material adverse impact on the trading
      price
      of our common stock.**




The
      reports of publicly-traded companies are subject to review by the SEC from
      time
      to time for the
      purpose of assisting companies in complying with applicable disclosure
      requirements and to enhance the overall effectiveness of companies public
      filings, and comprehensive reviews of such reports are now required at least
      every three years under the Sarbanes-Oxley Act of 2002. While we believe that
      our previously filed SEC reports comply, and we intend that all future reports
      will comply in all material respects with the published rules and regulations
      of
      the SEC, we could be required to modify or reformulate information contained
      in
      prior filings as a result of an SEC review.  Any modification or
      reformulation of information contained in such reports could be significant
      and
      result in material liability to us and have a material adverse impact on the
      trading price of our common stock.




-46-
 **Back
          to Table of Contents**





**We
      have been notified that we do not satisfy all of the continued listing criteria
      established by The Nasdaq National Market.**  **The
      liquidity of our common stock could be adversely affected if we are delisted
      from The Nasdaq National Market.**




On
      March
      16, 2006, we received a Nasdaq Staff Deficiency Letter dated March 14, 2006
      indicating that, based on our Form 10-Q for the period ended January 31, 2006,
      Nasdaq had determined that we are not in compliance with the minimum $10 million
      stockholders’ equity requirement for continued listing on The Nasdaq National
      Market set forth in Marketplace Rule 4450(a)(3). On April 28, 2006, we received
      a notice from Nasdaq stating that our securities will be delisted from The
      Nasdaq National Market at the opening of business on May 9, 2006, unless we
      requested a hearing in accordance with the Marketplace Rule 4800 Series. On
      May
      3, 2006, we requested a hearing with The Nasdaq Listing Qualifications Panel
      to
      appeal the Staff’s determination to delist our securities from the Nasdaq
      National Market. The hearing before the Panel to present our plan of compliance
      has been scheduled for June 15, 2006. On June 7, 2006, we completed a $24
      million private placement of shares of our common stock. As a result,
      we believe that we are now in compliance with the minimum stockholder's
      equity and other requirements for continued listing on The Nasdaq National
      Market. Upon review of our plan of compliance, including the recently
      completed private placement, Nasdaq will determine whether or not
      to delist our securities. If such delisting occurs, the market price and
      market liquidity of our common stock may be adversely affected.




Alternatively,
      if faced with such delisting, we may submit an application to transfer the
      listing of our common stock to The Nasdaq Capital Market. Among other
      requirements, The Nasdaq Capital Market has a minimum $2.5 million stockholders’
equity requirement for continued listing.




Alternatively,
      if our common stock is delisted by Nasdaq, our common stock may be eligible
      to
      trade on the American Stock Exchange, the OTC Bulletin Board maintained by
      Nasdaq, another over-the-counter quotation system, or on the pink sheets where
      an investor may find it more difficult to dispose of or obtain accurate
      quotations as to the market value of our common stock, although there can be
      no
      assurance that our common stock will be eligible for trading on any alternative
      exchanges or markets. In addition, we would be subject to Rule 15c2-11
      promulgated by the SEC. If we fail to meet criteria set forth in the rule (for
      example, by failing to file periodic reports as required by the Exchange Act),
      various practice requirements are imposed on broker-dealers who sell securities
      governed by the rule to persons other than established customers and accredited
      investors. For these types of transactions, the broker-dealer must make a
      special suitability determination for the purchaser and have received the
      purchaser's written consent to the transactions prior to sale. Consequently,
      such rule may deter broker-dealers from recommending or selling our common
      stock, which may further affect the liquidity of our common stock.




Delisting
      from Nasdaq would make trading our common stock more difficult for investors,
      potentially leading to further declines in our share price. It would also make
      it more difficult for us to raise additional capital.




-47-
 **Back
          to Table of Contents**
  **Item
        2. Unregistered Sales of Equity Securities and Use of
        Proceeds**




On
      March
      28, 2006, we issued a warrant to Partners for Growth, LLC as consideration
      for
      entering into a Loan and Security Agreement between the parties. The warrant
      entitles the holder, for a period of five years, to purchase up to an aggregate
      of 395,000 restricted shares of our common stock at a price of $1.89 per share.
      The warrant was issued in reliance on the exemption from registration contained
      in Section 4(2) of the Securities Act of 1933 as a transaction by an issuer
      not
      involving any public offering.





**Item
      6.****Exhibits**





(a)  Exhibits.





Exhibits
                No.
            
            Title31.1
            
            Certification
                of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
                Act of 200231.2
            
            Certification
                of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley
                Act of 200232.1
            
            Certification
                of Chief Executive Officer and Chief Financial Officer Pursuant to
                Section
                906 of the Sarbanes-Oxley Act of
                2002






-48-
 **Back
          to Table of Contents**




**SIGNATURES**




Pursuant
      to the requirements of the Securities Exchange Act of 1934, the Registrant
      has
      duly caused this report to be signed on its behalf by the undersigned thereunto
      duly authorized.




NORTH
      AMERICAN SCIENTIFIC, INC.




June
      9,
      2006


By: /s/
      L.
      Michael Cutrer


Name: L.
      Michael Cutrer


Title: President
      and Chief
      Executive Officer


(Principal
      Executive Officer)




June
      9,
      2006


By: /s/
      James
      W. Klingler





Name: James
      W.
      Klingler


Title: Senior
      Vice President and Chief
      Financial Officer


(Principal
      Financial Officer)




-49-